<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905006</url>
  </required_header>
  <id_info>
    <org_study_id>PS0010</org_study_id>
    <secondary_id>2016-001891-31</secondary_id>
    <nct_id>NCT02905006</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis</brief_title>
  <acronym>BE ABLE 1</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled,&#xD;
      parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics&#xD;
      (PK), and pharmacodynamics (PD) of Bimekizumab compared with placebo in adult subjects with&#xD;
      moderate to severe chronic plaque psoriasis in order to guide the selection of doses and&#xD;
      clinical indices in the Phase 3 development program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Bimekizumab During the Study</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).&#xD;
Values Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and confidence intervals (CIs). Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK (Apparent Total Clearance (CL/F)) of Bimekizumab</measure>
    <time_frame>From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)</time_frame>
    <description>The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK (Apparent Volume of Distribution (V/F)) of Bimekizumab</measure>
    <time_frame>From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)</time_frame>
    <description>The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Bimekizumab Leading to 50% of Maximum Effect (EC50)</measure>
    <time_frame>From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)</time_frame>
    <description>The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Positive Anti-bimekizumab Antibody (AbAb) Status Prior to Study Treatment</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Antibody positive status prior study treatment was defined as having an antibody level greater than (&gt;) 28.5% at Baseline (Week 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Overall Positive Anti-bimekizumab Antibody (AbAb) Status Following Study Treatment</measure>
    <time_frame>From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)</time_frame>
    <description>Overall antibody positive was defined as having a value of &gt; 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE) During the Study</measure>
    <time_frame>From Screening to End of Safety Follow-up (up to Week 32)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE) During the Study by Severity</measure>
    <time_frame>From Screening to End of Safety Follow-up (up to Week 32)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Platelets was measured in number of platelets per liter (10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Erythrocytes mean corpuscular volume was measured in femtolitres (fL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Erythrocytes was measured in number of red blood cells per liter (10^12/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Hematocrit was measured in volume percentage (%) of red blood cells in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Calcium, Chloride, Potassium, Magnesium, Sodium, Urea Nitrogen, Cholesterol, Glucose)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Lactate Dehydrogenase, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase were measured in units per liter (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Creatinine and bilirubin were measured in micromols per liter (μmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>C Reactive Protein was measured in milligrams per liters (mg/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (pH)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Urine pH was measured on a pH scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Leukocyte Esterase)</measure>
    <time_frame>From Baseline (Week 0) until Week 12</time_frame>
    <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Nitrite)</measure>
    <time_frame>From Baseline (Week 0) until Week 12</time_frame>
    <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Occult Blood)</measure>
    <time_frame>From Baseline (Week 0) until Week 12</time_frame>
    <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Urine Glucose)</measure>
    <time_frame>From Baseline (Week 0) until Week 12</time_frame>
    <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Albumin)</measure>
    <time_frame>From Baseline (Week 0) until Week 12</time_frame>
    <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Blood pressure was measured in millimeters of mercury (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Pulse rate was measured in beats per minute (beats/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Temperature)</measure>
    <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Temperature was measured in degrees Celsius (°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Physical Examination Abnormalities</measure>
    <time_frame>At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)</time_frame>
    <description>The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status.&#xD;
Any clinically significant abnormal findings during the study were captured as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
    <description>Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosing regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosing regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosing regimen 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimekizumab</intervention_name>
    <description>Subjects will be randomized to receive a combination of injections of Bimekizumab.</description>
    <arm_group_label>Bimekizumab dosing regimen 1</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 2</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 3</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 4</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 5</arm_group_label>
    <other_name>UCB4940</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.</description>
    <arm_group_label>Bimekizumab dosing regimen 1</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 2</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 3</arm_group_label>
    <arm_group_label>Bimekizumab dosing regimen 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent&#xD;
&#xD;
          -  Chronic plaque psoriasis for at least 6 months prior to Screening&#xD;
&#xD;
          -  PASI (Psoriasis Area and Severity Index) &gt;=12 and BSA (body surface area) &gt;=10% and&#xD;
             IGA (Investigator's Global Assessment) score 3 or greater on a 5-point scale&#xD;
&#xD;
          -  Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy&#xD;
&#xD;
          -  Female subjects must be postmenopausal, permanently sterilized or, if of childbearing&#xD;
             potential, must be willing to use a highly effective method of contraception up till&#xD;
             20 weeks after last administration of study drug&#xD;
&#xD;
          -  Male subjects with a partner of childbearing potential must be willing to use a condom&#xD;
             when sexually active, up till 20 weeks after the last administration of study&#xD;
             medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced&#xD;
             psoriasis&#xD;
&#xD;
          -  Subject has any severe, progressive and/or uncontrolled renal, hepatic, hematological,&#xD;
             endocrine, pulmonary, cardiac, gastrointestinal or neurological disease&#xD;
&#xD;
          -  Subject has any significant concurrent medical condition or laboratory abnormalities,&#xD;
             as defined in the study protocol&#xD;
&#xD;
          -  Subject taking prohibited psoriatic medications&#xD;
&#xD;
          -  Subject receiving any live vaccines within 8 weeks prior to the Baseline and subjects&#xD;
             receiving Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  Subject has previously received treatment with any anti-interleukin-17 (anti-IL-17)&#xD;
             therapy or has been exposed to more than 1 biological response modifier (limited to&#xD;
             anti-tumor necrosis factor (TNF) or IL-12/23) for psoriatic arthritis or psoriasis&#xD;
             prior to the Baseline&#xD;
&#xD;
          -  Subject has any current sign or symptom that may indicate an active infection (except&#xD;
             for common cold)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ps0010 711</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 708</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 706</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 704</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 718</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 738</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 736</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 712</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 733</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 702</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 709</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 203</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 204</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 201</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 206</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 205</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 214</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 209</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 214</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 300</name>
      <address>
        <city>Ostrava Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 303</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 301</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 304</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 404</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 400</name>
      <address>
        <city>Oroshaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 405</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 502</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 501</name>
      <address>
        <city>Shinaga Wa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 503</name>
      <address>
        <city>Tokio</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 504</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 600</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 611</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 605</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 610</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 604</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 608</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 606</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 603</name>
      <address>
        <city>Podlaski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 607</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 601</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0010 609</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <results_first_submitted>June 8, 2020</results_first_submitted>
  <results_first_submitted_qc>November 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <disposition_first_submitted>June 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2018</disposition_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Chronic Plaque Psoriasis</keyword>
  <keyword>Bimekizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02905006/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02905006/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll participants in August 2016 and concluded in July 2017.</recruitment_details>
      <pre_assignment_details>The study included a 2-4 week Screening Period and a 12-week Treatment Period. Completed study was defined as completed the 12-week double-blind Treatment Period. After Treatment Period participants either enrolled in an extension study (PS0011) or entered a 20-week Safety Follow-Up Period.&#xD;
Participant Flow refers to the Randomized Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).</description>
        </group>
        <group group_id="P2">
          <title>Bimekizumab 64 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="P3">
          <title>Bimekizumab 160 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="P4">
          <title>Bimekizumab 160 mg w/ LD Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="P5">
          <title>Bimekizumab 320 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="P6">
          <title>Bimekizumab 480 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in Extension Study (PS0011)</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Safety Follow-up Period</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening exclusion criteria met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lab withdrawal criterion met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive for Tuberculosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject positive for Hep B</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved abroad</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient randomized by mistake</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Safety Set, which consisted of all participants who received at least 1 dose of the study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).</description>
        </group>
        <group group_id="B2">
          <title>Bimekizumab 64 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="B3">
          <title>Bimekizumab 160 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="B4">
          <title>Bimekizumab 160 mg w/ LD Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="B5">
          <title>Bimekizumab 320 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="B6">
          <title>Bimekizumab 480 mg Q4W</title>
          <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.</description>
        </group>
        <group group_id="B7">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="43"/>
            <count group_id="B7" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="12.3"/>
                    <measurement group_id="B2" value="44.2" spread="13.8"/>
                    <measurement group_id="B3" value="43.4" spread="12.4"/>
                    <measurement group_id="B4" value="46.5" spread="15.2"/>
                    <measurement group_id="B5" value="42.6" spread="13.6"/>
                    <measurement group_id="B6" value="42.9" spread="15.2"/>
                    <measurement group_id="B7" value="44.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian/Alaskan native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
        <description>The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
          <description>The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="67.4"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="79.1"/>
                    <measurement group_id="O6" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 12</title>
        <description>The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 12</title>
          <description>The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="51.3"/>
                    <measurement group_id="O3" value="74.4"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="86.0"/>
                    <measurement group_id="O6" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>21.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.51</ci_lower_limit>
            <ci_upper_limit>101.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>63.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.90</ci_lower_limit>
            <ci_upper_limit>309.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>62.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.61</ci_lower_limit>
            <ci_upper_limit>308.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>130.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.50</ci_lower_limit>
            <ci_upper_limit>693.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>69.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.07</ci_lower_limit>
            <ci_upper_limit>342.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 8</title>
        <description>The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.</description>
        <time_frame>Week 8</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 8</title>
          <description>The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="62.8"/>
                    <measurement group_id="O4" value="77.5"/>
                    <measurement group_id="O5" value="86.0"/>
                    <measurement group_id="O6" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0003</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>18.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.79</ci_lower_limit>
            <ci_upper_limit>87.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>39.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.19</ci_lower_limit>
            <ci_upper_limit>191.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>77.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.19</ci_lower_limit>
            <ci_upper_limit>392.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>141.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.26</ci_lower_limit>
            <ci_upper_limit>767.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>58.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.89</ci_lower_limit>
            <ci_upper_limit>288.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 8</title>
        <description>The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
        <time_frame>Week 8</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 8</title>
          <description>The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="41.0"/>
                    <measurement group_id="O3" value="58.1"/>
                    <measurement group_id="O4" value="67.5"/>
                    <measurement group_id="O5" value="86.0"/>
                    <measurement group_id="O6" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
        <description>The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
          <description>The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="61.5"/>
                    <measurement group_id="O3" value="81.4"/>
                    <measurement group_id="O4" value="85.0"/>
                    <measurement group_id="O5" value="93.0"/>
                    <measurement group_id="O6" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>32.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.82</ci_lower_limit>
            <ci_upper_limit>156.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>94.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.54</ci_lower_limit>
            <ci_upper_limit>481.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>117.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.08</ci_lower_limit>
            <ci_upper_limit>626.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>280.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.06</ci_lower_limit>
            <ci_upper_limit>1789.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>107.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.82</ci_lower_limit>
            <ci_upper_limit>558.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
        <description>PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (FAS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
          <description>PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12.</description>
          <population>The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="27.9"/>
                    <measurement group_id="O4" value="60.0"/>
                    <measurement group_id="O5" value="55.8"/>
                    <measurement group_id="O6" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0002</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Bimekizumab During the Study</title>
        <description>Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).&#xD;
Values Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and confidence intervals (CIs). Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point.</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimekizumab 64 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 160 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg w/ LD Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 320 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 480 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Bimekizumab During the Study</title>
          <description>Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).&#xD;
Values Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and confidence intervals (CIs). Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point.</description>
          <population>The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection; Participants had no prior BKZ treatment.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection; Participants had no prior BKZ treatment.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection; Participants had no prior BKZ treatment.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection; Participants had no prior BKZ treatment.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection; Participants had no prior BKZ treatment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4490" lower_limit="3.7526" upper_limit="5.2746"/>
                    <measurement group_id="O2" value="9.2481" lower_limit="6.9779" upper_limit="12.2569"/>
                    <measurement group_id="O3" value="20.7892" lower_limit="14.9192" upper_limit="28.9688"/>
                    <measurement group_id="O4" value="21.8622" lower_limit="16.0624" upper_limit="29.7563"/>
                    <measurement group_id="O5" value="31.8019" lower_limit="23.3488" upper_limit="43.3154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4704" lower_limit="3.0167" upper_limit="3.9923"/>
                    <measurement group_id="O2" value="8.6862" lower_limit="7.5316" upper_limit="10.0179"/>
                    <measurement group_id="O3" value="19.0428" lower_limit="16.5381" upper_limit="21.9267"/>
                    <measurement group_id="O4" value="19.0324" lower_limit="16.8925" upper_limit="21.4434"/>
                    <measurement group_id="O5" value="27.5641" lower_limit="23.8485" upper_limit="31.8586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1282" lower_limit="1.8398" upper_limit="2.4617"/>
                    <measurement group_id="O2" value="5.3751" lower_limit="4.5233" upper_limit="6.3872"/>
                    <measurement group_id="O3" value="11.2903" lower_limit="9.4809" upper_limit="13.4450"/>
                    <measurement group_id="O4" value="11.9194" lower_limit="10.4503" upper_limit="13.5951"/>
                    <measurement group_id="O5" value="17.1811" lower_limit="14.7612" upper_limit="19.9977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3069" lower_limit="1.7780" upper_limit="2.9931"/>
                    <measurement group_id="O2" value="7.1859" lower_limit="5.3747" upper_limit="9.6075"/>
                    <measurement group_id="O3" value="10.2208" lower_limit="8.8561" upper_limit="11.7957"/>
                    <measurement group_id="O4" value="16.3187" lower_limit="13.9947" upper_limit="19.0285"/>
                    <measurement group_id="O5" value="23.3285" lower_limit="19.8863" upper_limit="27.3665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3121" lower_limit="1.6037" upper_limit="3.3335"/>
                    <measurement group_id="O2" value="9.5278" lower_limit="8.0614" upper_limit="11.2608"/>
                    <measurement group_id="O3" value="10.2557" lower_limit="8.6807" upper_limit="12.1165"/>
                    <measurement group_id="O4" value="18.3166" lower_limit="15.1652" upper_limit="22.1228"/>
                    <measurement group_id="O5" value="28.0908" lower_limit="23.2463" upper_limit="33.9448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O5" value="0.5165" lower_limit="0.0032" upper_limit="84.5222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK (Apparent Total Clearance (CL/F)) of Bimekizumab</title>
        <description>The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
        <time_frame>From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)</time_frame>
        <population>The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK (Apparent Total Clearance (CL/F)) of Bimekizumab</title>
          <description>The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
          <population>The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.</population>
          <units>L/Day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.362" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK (Apparent Volume of Distribution (V/F)) of Bimekizumab</title>
        <description>The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
        <time_frame>From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)</time_frame>
        <population>The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK (Apparent Volume of Distribution (V/F)) of Bimekizumab</title>
          <description>The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
          <population>The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Bimekizumab Leading to 50% of Maximum Effect (EC50)</title>
        <description>The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
        <time_frame>From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)</time_frame>
        <population>The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. EC50 was estimated based on all available data and cannot be derived for each treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Bimekizumab Leading to 50% of Maximum Effect (EC50)</title>
          <description>The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.&#xD;
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.</description>
          <population>The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. EC50 was estimated based on all available data and cannot be derived for each treatment arm.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Positive Anti-bimekizumab Antibody (AbAb) Status Prior to Study Treatment</title>
        <description>Antibody positive status prior study treatment was defined as having an antibody level greater than (&gt;) 28.5% at Baseline (Week 0).</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PK-PPS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Pharmacokinetics Per-Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Positive Anti-bimekizumab Antibody (AbAb) Status Prior to Study Treatment</title>
          <description>Antibody positive status prior study treatment was defined as having an antibody level greater than (&gt;) 28.5% at Baseline (Week 0).</description>
          <population>The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Overall Positive Anti-bimekizumab Antibody (AbAb) Status Following Study Treatment</title>
        <description>Overall antibody positive was defined as having a value of &gt; 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.</description>
        <time_frame>From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)</time_frame>
        <population>The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PK-PPS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Pharmacokinetics Per-Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (PK-PPS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Overall Positive Anti-bimekizumab Antibody (AbAb) Status Following Study Treatment</title>
          <description>Overall antibody positive was defined as having a value of &gt; 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.</description>
          <population>The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE) During the Study</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
        <time_frame>From Screening to End of Safety Follow-up (up to Week 32)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE) During the Study</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="76.9"/>
                    <measurement group_id="O3" value="55.8"/>
                    <measurement group_id="O4" value="65.0"/>
                    <measurement group_id="O5" value="60.5"/>
                    <measurement group_id="O6" value="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE) During the Study by Severity</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
        <time_frame>From Screening to End of Safety Follow-up (up to Week 32)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE) During the Study by Severity</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="43.6"/>
                    <measurement group_id="O3" value="27.9"/>
                    <measurement group_id="O4" value="22.5"/>
                    <measurement group_id="O5" value="39.5"/>
                    <measurement group_id="O6" value="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="27.9"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="20.9"/>
                    <measurement group_id="O6" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)</title>
        <description>Platelets was measured in number of platelets per liter (10^9/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)</title>
          <description>Platelets was measured in number of platelets per liter (10^9/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>10^9 platelets per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="34.7"/>
                    <measurement group_id="O2" value="3.2" spread="21.0"/>
                    <measurement group_id="O3" value="-4.6" spread="30.8"/>
                    <measurement group_id="O4" value="-14.0" spread="30.8"/>
                    <measurement group_id="O5" value="3.5" spread="25.2"/>
                    <measurement group_id="O6" value="-0.1" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="37.8"/>
                    <measurement group_id="O2" value="-8.6" spread="26.8"/>
                    <measurement group_id="O3" value="-5.6" spread="36.4"/>
                    <measurement group_id="O4" value="-8.9" spread="27.8"/>
                    <measurement group_id="O5" value="7.8" spread="31.2"/>
                    <measurement group_id="O6" value="-3.9" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="32.0"/>
                    <measurement group_id="O2" value="-5.8" spread="28.3"/>
                    <measurement group_id="O3" value="-8.6" spread="40.1"/>
                    <measurement group_id="O4" value="-11.4" spread="21.8"/>
                    <measurement group_id="O5" value="-7.0" spread="28.9"/>
                    <measurement group_id="O6" value="-7.5" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="47.5"/>
                    <measurement group_id="O2" value="-5.2" spread="26.3"/>
                    <measurement group_id="O3" value="-13.6" spread="34.3"/>
                    <measurement group_id="O4" value="-5.6" spread="30.3"/>
                    <measurement group_id="O5" value="-0.3" spread="44.0"/>
                    <measurement group_id="O6" value="-7.6" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="37.6"/>
                    <measurement group_id="O2" value="-2.3" spread="44.7"/>
                    <measurement group_id="O3" value="-6.1" spread="43.7"/>
                    <measurement group_id="O4" value="6.3" spread="35.6"/>
                    <measurement group_id="O5" value="0.7" spread="39.5"/>
                    <measurement group_id="O6" value="-4.7" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="36.7"/>
                    <measurement group_id="O2" value="-6.0" spread="36.2"/>
                    <measurement group_id="O3" value="-13.2" spread="40.1"/>
                    <measurement group_id="O4" value="-3.6" spread="37.5"/>
                    <measurement group_id="O5" value="-5.4" spread="36.1"/>
                    <measurement group_id="O6" value="-5.5" spread="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="33.3"/>
                    <measurement group_id="O2" value="-30.3" spread="71.6"/>
                    <measurement group_id="O3" value="7.8" spread="20.0"/>
                    <measurement group_id="O4" value="-33.0" spread="31.1"/>
                    <measurement group_id="O5" value="39.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="39.3" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)</title>
        <description>Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)</title>
          <description>Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ery. mean corpuscular HGB Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="8.1"/>
                    <measurement group_id="O2" value="-2.0" spread="10.3"/>
                    <measurement group_id="O3" value="-0.3" spread="8.8"/>
                    <measurement group_id="O4" value="-1.0" spread="11.6"/>
                    <measurement group_id="O5" value="0.5" spread="8.6"/>
                    <measurement group_id="O6" value="0.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. mean corpuscular HGB Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="7.9"/>
                    <measurement group_id="O2" value="1.1" spread="6.6"/>
                    <measurement group_id="O3" value="1.6" spread="9.4"/>
                    <measurement group_id="O4" value="-0.3" spread="9.8"/>
                    <measurement group_id="O5" value="2.6" spread="7.9"/>
                    <measurement group_id="O6" value="1.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. mean corpuscular HGB Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="9.1"/>
                    <measurement group_id="O2" value="0.2" spread="8.3"/>
                    <measurement group_id="O3" value="-0.1" spread="9.9"/>
                    <measurement group_id="O4" value="-2.9" spread="6.3"/>
                    <measurement group_id="O5" value="0.1" spread="8.0"/>
                    <measurement group_id="O6" value="-0.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. mean corpuscular HGB Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="11.0"/>
                    <measurement group_id="O2" value="-1.7" spread="8.6"/>
                    <measurement group_id="O3" value="-0.5" spread="9.4"/>
                    <measurement group_id="O4" value="-2.9" spread="7.0"/>
                    <measurement group_id="O5" value="-0.5" spread="7.8"/>
                    <measurement group_id="O6" value="-1.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. mean corpuscular HGB Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="8.0"/>
                    <measurement group_id="O2" value="-1.4" spread="12.7"/>
                    <measurement group_id="O3" value="0.3" spread="10.3"/>
                    <measurement group_id="O4" value="-2.5" spread="7.9"/>
                    <measurement group_id="O5" value="-2.1" spread="9.2"/>
                    <measurement group_id="O6" value="-2.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. mean corpuscular HGB Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="12.5"/>
                    <measurement group_id="O2" value="-2.2" spread="14.7"/>
                    <measurement group_id="O3" value="-1.6" spread="9.1"/>
                    <measurement group_id="O4" value="-4.5" spread="10.1"/>
                    <measurement group_id="O5" value="-2.0" spread="12.7"/>
                    <measurement group_id="O6" value="-3.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. mean corpuscular HGB SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="11.0"/>
                    <measurement group_id="O2" value="5.3" spread="26.2"/>
                    <measurement group_id="O3" value="-5.5" spread="10.6"/>
                    <measurement group_id="O4" value="-9.5" spread="7.8"/>
                    <measurement group_id="O5" value="-2.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-22.0" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="7.3"/>
                    <measurement group_id="O2" value="0.1" spread="6.1"/>
                    <measurement group_id="O3" value="1.0" spread="6.8"/>
                    <measurement group_id="O4" value="-2.6" spread="5.2"/>
                    <measurement group_id="O5" value="-1.0" spread="7.0"/>
                    <measurement group_id="O6" value="-0.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="6.7"/>
                    <measurement group_id="O2" value="0.5" spread="5.3"/>
                    <measurement group_id="O3" value="0.6" spread="6.0"/>
                    <measurement group_id="O4" value="-1.5" spread="7.5"/>
                    <measurement group_id="O5" value="-1.1" spread="7.0"/>
                    <measurement group_id="O6" value="0.5" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="8.2"/>
                    <measurement group_id="O2" value="0.8" spread="6.1"/>
                    <measurement group_id="O3" value="-0.9" spread="6.2"/>
                    <measurement group_id="O4" value="-2.1" spread="5.9"/>
                    <measurement group_id="O5" value="-1.8" spread="8.7"/>
                    <measurement group_id="O6" value="-0.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="7.8"/>
                    <measurement group_id="O2" value="0.7" spread="6.3"/>
                    <measurement group_id="O3" value="-0.3" spread="6.6"/>
                    <measurement group_id="O4" value="-1.2" spread="4.8"/>
                    <measurement group_id="O5" value="-2.1" spread="8.4"/>
                    <measurement group_id="O6" value="0.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="8.0"/>
                    <measurement group_id="O2" value="1.1" spread="7.6"/>
                    <measurement group_id="O3" value="0.8" spread="7.1"/>
                    <measurement group_id="O4" value="-0.6" spread="7.5"/>
                    <measurement group_id="O5" value="-1.8" spread="8.1"/>
                    <measurement group_id="O6" value="0.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="9.1"/>
                    <measurement group_id="O2" value="3.2" spread="9.6"/>
                    <measurement group_id="O3" value="-0.1" spread="8.1"/>
                    <measurement group_id="O4" value="-1.0" spread="8.5"/>
                    <measurement group_id="O5" value="-1.2" spread="9.3"/>
                    <measurement group_id="O6" value="0.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="7.4"/>
                    <measurement group_id="O2" value="7.8" spread="31.0"/>
                    <measurement group_id="O3" value="-6.5" spread="4.7"/>
                    <measurement group_id="O4" value="-8.5" spread="2.1"/>
                    <measurement group_id="O5" value="6.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-6.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))</title>
        <description>Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))</title>
          <description>Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>picograms (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.57"/>
                    <measurement group_id="O2" value="-0.01" spread="0.56"/>
                    <measurement group_id="O3" value="-0.10" spread="0.55"/>
                    <measurement group_id="O4" value="0.07" spread="0.51"/>
                    <measurement group_id="O5" value="-0.09" spread="0.87"/>
                    <measurement group_id="O6" value="0.00" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.59"/>
                    <measurement group_id="O2" value="0.04" spread="0.54"/>
                    <measurement group_id="O3" value="0.05" spread="0.49"/>
                    <measurement group_id="O4" value="0.10" spread="0.78"/>
                    <measurement group_id="O5" value="-0.03" spread="0.60"/>
                    <measurement group_id="O6" value="0.14" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.66"/>
                    <measurement group_id="O2" value="0.10" spread="0.84"/>
                    <measurement group_id="O3" value="-0.07" spread="0.63"/>
                    <measurement group_id="O4" value="-0.01" spread="0.42"/>
                    <measurement group_id="O5" value="-0.10" spread="0.68"/>
                    <measurement group_id="O6" value="0.04" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.64"/>
                    <measurement group_id="O2" value="-0.09" spread="0.84"/>
                    <measurement group_id="O3" value="-0.16" spread="0.61"/>
                    <measurement group_id="O4" value="-0.11" spread="0.47"/>
                    <measurement group_id="O5" value="-0.12" spread="0.84"/>
                    <measurement group_id="O6" value="-0.04" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.64"/>
                    <measurement group_id="O2" value="0.09" spread="1.09"/>
                    <measurement group_id="O3" value="-0.16" spread="1.10"/>
                    <measurement group_id="O4" value="-0.16" spread="0.64"/>
                    <measurement group_id="O5" value="-0.26" spread="0.99"/>
                    <measurement group_id="O6" value="-0.16" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.71"/>
                    <measurement group_id="O2" value="0.09" spread="1.53"/>
                    <measurement group_id="O3" value="-0.08" spread="0.58"/>
                    <measurement group_id="O4" value="-0.14" spread="0.66"/>
                    <measurement group_id="O5" value="-0.09" spread="1.14"/>
                    <measurement group_id="O6" value="-0.16" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.79"/>
                    <measurement group_id="O2" value="2.93" spread="6.66"/>
                    <measurement group_id="O3" value="-0.15" spread="0.17"/>
                    <measurement group_id="O4" value="-0.55" spread="0.78"/>
                    <measurement group_id="O5" value="0.70" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.60" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)</title>
        <description>Erythrocytes mean corpuscular volume was measured in femtolitres (fL).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)</title>
          <description>Erythrocytes mean corpuscular volume was measured in femtolitres (fL).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>femtolitres (fL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="1.55"/>
                    <measurement group_id="O2" value="0.52" spread="2.29"/>
                    <measurement group_id="O3" value="-0.25" spread="1.64"/>
                    <measurement group_id="O4" value="0.51" spread="2.63"/>
                    <measurement group_id="O5" value="-0.23" spread="2.14"/>
                    <measurement group_id="O6" value="-0.04" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="1.65"/>
                    <measurement group_id="O2" value="-0.16" spread="1.31"/>
                    <measurement group_id="O3" value="-0.33" spread="1.96"/>
                    <measurement group_id="O4" value="0.31" spread="1.32"/>
                    <measurement group_id="O5" value="-0.64" spread="1.40"/>
                    <measurement group_id="O6" value="-0.05" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="1.60"/>
                    <measurement group_id="O2" value="0.23" spread="1.89"/>
                    <measurement group_id="O3" value="-0.25" spread="1.81"/>
                    <measurement group_id="O4" value="0.67" spread="1.76"/>
                    <measurement group_id="O5" value="-0.10" spread="1.64"/>
                    <measurement group_id="O6" value="0.22" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="2.84"/>
                    <measurement group_id="O2" value="0.14" spread="2.47"/>
                    <measurement group_id="O3" value="-0.29" spread="1.90"/>
                    <measurement group_id="O4" value="0.39" spread="1.79"/>
                    <measurement group_id="O5" value="-0.02" spread="1.92"/>
                    <measurement group_id="O6" value="0.25" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="2.11"/>
                    <measurement group_id="O2" value="0.71" spread="2.88"/>
                    <measurement group_id="O3" value="-0.54" spread="2.57"/>
                    <measurement group_id="O4" value="0.16" spread="2.57"/>
                    <measurement group_id="O5" value="-0.02" spread="2.29"/>
                    <measurement group_id="O6" value="0.36" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="3.81"/>
                    <measurement group_id="O2" value="0.87" spread="3.23"/>
                    <measurement group_id="O3" value="0.17" spread="2.39"/>
                    <measurement group_id="O4" value="0.78" spread="2.55"/>
                    <measurement group_id="O5" value="0.47" spread="2.88"/>
                    <measurement group_id="O6" value="0.51" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="5.10"/>
                    <measurement group_id="O2" value="7.80" spread="14.07"/>
                    <measurement group_id="O3" value="0.90" spread="2.38"/>
                    <measurement group_id="O4" value="0.85" spread="0.35"/>
                    <measurement group_id="O5" value="2.80" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="4.87" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)</title>
        <description>Erythrocytes was measured in number of red blood cells per liter (10^12/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)</title>
          <description>Erythrocytes was measured in number of red blood cells per liter (10^12/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>10^12 red blood cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.081" spread="0.282"/>
                    <measurement group_id="O2" value="0.004" spread="0.213"/>
                    <measurement group_id="O3" value="0.047" spread="0.238"/>
                    <measurement group_id="O4" value="-0.095" spread="0.184"/>
                    <measurement group_id="O5" value="-0.029" spread="0.259"/>
                    <measurement group_id="O6" value="-0.026" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.088" spread="0.220"/>
                    <measurement group_id="O2" value="0.010" spread="0.193"/>
                    <measurement group_id="O3" value="0.014" spread="0.215"/>
                    <measurement group_id="O4" value="-0.060" spread="0.282"/>
                    <measurement group_id="O5" value="-0.041" spread="0.231"/>
                    <measurement group_id="O6" value="-0.001" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="0.274"/>
                    <measurement group_id="O2" value="0.019" spread="0.217"/>
                    <measurement group_id="O3" value="-0.018" spread="0.193"/>
                    <measurement group_id="O4" value="-0.066" spread="0.215"/>
                    <measurement group_id="O5" value="-0.053" spread="0.281"/>
                    <measurement group_id="O6" value="-0.015" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="0.277"/>
                    <measurement group_id="O2" value="0.038" spread="0.218"/>
                    <measurement group_id="O3" value="0.011" spread="0.243"/>
                    <measurement group_id="O4" value="-0.019" spread="0.145"/>
                    <measurement group_id="O5" value="-0.060" spread="0.278"/>
                    <measurement group_id="O6" value="0.035" spread="0.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" spread="0.320"/>
                    <measurement group_id="O2" value="0.022" spread="0.245"/>
                    <measurement group_id="O3" value="0.048" spread="0.219"/>
                    <measurement group_id="O4" value="0.009" spread="0.224"/>
                    <measurement group_id="O5" value="-0.028" spread="0.240"/>
                    <measurement group_id="O6" value="0.056" spread="0.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.314"/>
                    <measurement group_id="O2" value="0.092" spread="0.258"/>
                    <measurement group_id="O3" value="0.011" spread="0.271"/>
                    <measurement group_id="O4" value="-0.005" spread="0.297"/>
                    <measurement group_id="O5" value="-0.036" spread="0.297"/>
                    <measurement group_id="O6" value="0.039" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.090" spread="0.346"/>
                    <measurement group_id="O2" value="-0.135" spread="0.184"/>
                    <measurement group_id="O3" value="-0.195" spread="0.165"/>
                    <measurement group_id="O4" value="-0.215" spread="0.035"/>
                    <measurement group_id="O5" value="0.080" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.123" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)</title>
        <description>Hematocrit was measured in volume percentage (%) of red blood cells in blood.</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)</title>
          <description>Hematocrit was measured in volume percentage (%) of red blood cells in blood.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>volume % of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="2.49"/>
                    <measurement group_id="O2" value="0.27" spread="2.07"/>
                    <measurement group_id="O3" value="0.33" spread="2.31"/>
                    <measurement group_id="O4" value="-0.58" spread="2.14"/>
                    <measurement group_id="O5" value="-0.36" spread="2.31"/>
                    <measurement group_id="O6" value="-0.23" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="2.02"/>
                    <measurement group_id="O2" value="0.00" spread="1.65"/>
                    <measurement group_id="O3" value="-0.04" spread="2.15"/>
                    <measurement group_id="O4" value="-0.42" spread="2.61"/>
                    <measurement group_id="O5" value="-0.65" spread="2.09"/>
                    <measurement group_id="O6" value="-0.02" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="2.40"/>
                    <measurement group_id="O2" value="0.24" spread="2.07"/>
                    <measurement group_id="O3" value="-0.26" spread="1.86"/>
                    <measurement group_id="O4" value="-0.26" spread="1.80"/>
                    <measurement group_id="O5" value="-0.48" spread="2.57"/>
                    <measurement group_id="O6" value="-0.03" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="2.46"/>
                    <measurement group_id="O2" value="0.41" spread="1.88"/>
                    <measurement group_id="O3" value="-0.04" spread="2.18"/>
                    <measurement group_id="O4" value="0.02" spread="1.73"/>
                    <measurement group_id="O5" value="-0.51" spread="2.59"/>
                    <measurement group_id="O6" value="0.44" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="2.37"/>
                    <measurement group_id="O2" value="0.55" spread="2.51"/>
                    <measurement group_id="O3" value="0.18" spread="1.84"/>
                    <measurement group_id="O4" value="0.14" spread="2.61"/>
                    <measurement group_id="O5" value="-0.22" spread="2.46"/>
                    <measurement group_id="O6" value="0.67" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="2.87"/>
                    <measurement group_id="O2" value="1.25" spread="2.29"/>
                    <measurement group_id="O3" value="0.18" spread="2.57"/>
                    <measurement group_id="O4" value="0.30" spread="2.99"/>
                    <measurement group_id="O5" value="-0.05" spread="2.75"/>
                    <measurement group_id="O6" value="0.59" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="1.44"/>
                    <measurement group_id="O2" value="1.98" spread="6.92"/>
                    <measurement group_id="O3" value="-1.20" spread="1.90"/>
                    <measurement group_id="O4" value="-1.50" spread="0.14"/>
                    <measurement group_id="O5" value="2.10" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="1.00" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)</title>
        <description>Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10^9/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)</title>
          <description>Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10^9/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>10^9 white blood cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                    <measurement group_id="O2" value="0.01" spread="0.03"/>
                    <measurement group_id="O3" value="0.00" spread="0.03"/>
                    <measurement group_id="O4" value="0.01" spread="0.03"/>
                    <measurement group_id="O5" value="0.00" spread="0.04"/>
                    <measurement group_id="O6" value="0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.02"/>
                    <measurement group_id="O2" value="0.00" spread="0.04"/>
                    <measurement group_id="O3" value="0.01" spread="0.04"/>
                    <measurement group_id="O4" value="0.01" spread="0.04"/>
                    <measurement group_id="O5" value="0.01" spread="0.04"/>
                    <measurement group_id="O6" value="0.00" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.05"/>
                    <measurement group_id="O3" value="0.00" spread="0.03"/>
                    <measurement group_id="O4" value="0.01" spread="0.02"/>
                    <measurement group_id="O5" value="0.01" spread="0.05"/>
                    <measurement group_id="O6" value="0.00" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.04"/>
                    <measurement group_id="O3" value="0.00" spread="0.04"/>
                    <measurement group_id="O4" value="0.01" spread="0.02"/>
                    <measurement group_id="O5" value="0.00" spread="0.04"/>
                    <measurement group_id="O6" value="0.00" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.04"/>
                    <measurement group_id="O2" value="-0.01" spread="0.04"/>
                    <measurement group_id="O3" value="0.02" spread="0.01"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.02" spread="0.04"/>
                    <measurement group_id="O6" value="0.00" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.04"/>
                    <measurement group_id="O3" value="0.01" spread="0.03"/>
                    <measurement group_id="O4" value="0.00" spread="0.02"/>
                    <measurement group_id="O5" value="0.01" spread="0.04"/>
                    <measurement group_id="O6" value="0.00" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.05"/>
                    <measurement group_id="O2" value="-0.03" spread="0.05"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.00" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.06"/>
                    <measurement group_id="O2" value="0.02" spread="0.12"/>
                    <measurement group_id="O3" value="0.01" spread="0.07"/>
                    <measurement group_id="O4" value="0.04" spread="0.10"/>
                    <measurement group_id="O5" value="0.02" spread="0.11"/>
                    <measurement group_id="O6" value="-0.02" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.08"/>
                    <measurement group_id="O2" value="0.04" spread="0.26"/>
                    <measurement group_id="O3" value="0.00" spread="0.08"/>
                    <measurement group_id="O4" value="0.05" spread="0.11"/>
                    <measurement group_id="O5" value="0.00" spread="0.11"/>
                    <measurement group_id="O6" value="0.01" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.09"/>
                    <measurement group_id="O2" value="0.04" spread="0.26"/>
                    <measurement group_id="O3" value="0.01" spread="0.08"/>
                    <measurement group_id="O4" value="0.02" spread="0.11"/>
                    <measurement group_id="O5" value="0.03" spread="0.09"/>
                    <measurement group_id="O6" value="0.00" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.10"/>
                    <measurement group_id="O2" value="0.02" spread="0.19"/>
                    <measurement group_id="O3" value="0.00" spread="0.08"/>
                    <measurement group_id="O4" value="0.01" spread="0.09"/>
                    <measurement group_id="O5" value="0.05" spread="0.16"/>
                    <measurement group_id="O6" value="-0.01" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.09"/>
                    <measurement group_id="O2" value="0.01" spread="0.18"/>
                    <measurement group_id="O3" value="0.01" spread="0.08"/>
                    <measurement group_id="O4" value="0.04" spread="0.17"/>
                    <measurement group_id="O5" value="0.05" spread="0.18"/>
                    <measurement group_id="O6" value="-0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.09"/>
                    <measurement group_id="O2" value="0.03" spread="0.22"/>
                    <measurement group_id="O3" value="0.00" spread="0.09"/>
                    <measurement group_id="O4" value="0.00" spread="0.08"/>
                    <measurement group_id="O5" value="0.03" spread="0.13"/>
                    <measurement group_id="O6" value="-0.03" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.06"/>
                    <measurement group_id="O2" value="0.08" spread="0.10"/>
                    <measurement group_id="O3" value="0.10" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="-0.10" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.07" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="1.30"/>
                    <measurement group_id="O2" value="-0.59" spread="1.34"/>
                    <measurement group_id="O3" value="-0.15" spread="1.43"/>
                    <measurement group_id="O4" value="-0.63" spread="1.82"/>
                    <measurement group_id="O5" value="-0.19" spread="1.51"/>
                    <measurement group_id="O6" value="-0.48" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="1.36"/>
                    <measurement group_id="O2" value="-0.56" spread="1.31"/>
                    <measurement group_id="O3" value="-0.22" spread="1.43"/>
                    <measurement group_id="O4" value="-0.42" spread="1.34"/>
                    <measurement group_id="O5" value="-0.31" spread="1.80"/>
                    <measurement group_id="O6" value="-0.46" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.51"/>
                    <measurement group_id="O2" value="-0.36" spread="1.31"/>
                    <measurement group_id="O3" value="-0.23" spread="1.38"/>
                    <measurement group_id="O4" value="-0.54" spread="1.14"/>
                    <measurement group_id="O5" value="-0.36" spread="1.73"/>
                    <measurement group_id="O6" value="-0.34" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.25"/>
                    <measurement group_id="O2" value="-0.50" spread="1.95"/>
                    <measurement group_id="O3" value="-0.47" spread="1.49"/>
                    <measurement group_id="O4" value="-0.57" spread="1.34"/>
                    <measurement group_id="O5" value="-0.45" spread="2.02"/>
                    <measurement group_id="O6" value="-0.45" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="1.34"/>
                    <measurement group_id="O2" value="-0.67" spread="1.55"/>
                    <measurement group_id="O3" value="-0.24" spread="1.94"/>
                    <measurement group_id="O4" value="-0.37" spread="1.55"/>
                    <measurement group_id="O5" value="-0.30" spread="1.76"/>
                    <measurement group_id="O6" value="-0.45" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="1.37"/>
                    <measurement group_id="O2" value="-0.28" spread="1.68"/>
                    <measurement group_id="O3" value="-0.47" spread="1.67"/>
                    <measurement group_id="O4" value="-0.51" spread="1.41"/>
                    <measurement group_id="O5" value="-0.50" spread="1.44"/>
                    <measurement group_id="O6" value="-0.48" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.98"/>
                    <measurement group_id="O2" value="1.15" spread="2.54"/>
                    <measurement group_id="O3" value="0.95" spread="1.43"/>
                    <measurement group_id="O4" value="-0.65" spread="0.78"/>
                    <measurement group_id="O5" value="0.20" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.30" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.36"/>
                    <measurement group_id="O2" value="-0.05" spread="0.30"/>
                    <measurement group_id="O3" value="0.15" spread="0.42"/>
                    <measurement group_id="O4" value="0.13" spread="0.34"/>
                    <measurement group_id="O5" value="0.14" spread="0.46"/>
                    <measurement group_id="O6" value="0.00" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.32"/>
                    <measurement group_id="O2" value="-0.11" spread="0.30"/>
                    <measurement group_id="O3" value="0.09" spread="0.34"/>
                    <measurement group_id="O4" value="0.09" spread="0.40"/>
                    <measurement group_id="O5" value="0.12" spread="0.34"/>
                    <measurement group_id="O6" value="-0.08" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.40"/>
                    <measurement group_id="O2" value="-0.04" spread="0.33"/>
                    <measurement group_id="O3" value="0.15" spread="0.43"/>
                    <measurement group_id="O4" value="0.08" spread="0.42"/>
                    <measurement group_id="O5" value="0.11" spread="0.36"/>
                    <measurement group_id="O6" value="0.06" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.46"/>
                    <measurement group_id="O2" value="-0.08" spread="0.43"/>
                    <measurement group_id="O3" value="0.03" spread="0.31"/>
                    <measurement group_id="O4" value="0.04" spread="0.43"/>
                    <measurement group_id="O5" value="0.05" spread="0.37"/>
                    <measurement group_id="O6" value="-0.05" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.37"/>
                    <measurement group_id="O2" value="-0.04" spread="0.31"/>
                    <measurement group_id="O3" value="0.09" spread="0.40"/>
                    <measurement group_id="O4" value="0.11" spread="0.33"/>
                    <measurement group_id="O5" value="0.15" spread="0.45"/>
                    <measurement group_id="O6" value="0.06" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.38"/>
                    <measurement group_id="O2" value="0.01" spread="0.35"/>
                    <measurement group_id="O3" value="0.06" spread="0.38"/>
                    <measurement group_id="O4" value="0.07" spread="0.48"/>
                    <measurement group_id="O5" value="0.14" spread="0.38"/>
                    <measurement group_id="O6" value="-0.04" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.24"/>
                    <measurement group_id="O2" value="0.25" spread="0.40"/>
                    <measurement group_id="O3" value="0.23" spread="0.19"/>
                    <measurement group_id="O4" value="0.25" spread="0.21"/>
                    <measurement group_id="O5" value="0.00" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.50" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.16"/>
                    <measurement group_id="O2" value="-0.01" spread="0.12"/>
                    <measurement group_id="O3" value="0.02" spread="0.15"/>
                    <measurement group_id="O4" value="0.02" spread="0.11"/>
                    <measurement group_id="O5" value="0.02" spread="0.17"/>
                    <measurement group_id="O6" value="-0.03" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.14"/>
                    <measurement group_id="O2" value="-0.04" spread="0.13"/>
                    <measurement group_id="O3" value="0.00" spread="0.14"/>
                    <measurement group_id="O4" value="0.04" spread="0.15"/>
                    <measurement group_id="O5" value="-0.04" spread="0.17"/>
                    <measurement group_id="O6" value="-0.03" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="-0.01" spread="0.11"/>
                    <measurement group_id="O3" value="0.01" spread="0.15"/>
                    <measurement group_id="O4" value="0.03" spread="0.13"/>
                    <measurement group_id="O5" value="-0.01" spread="0.17"/>
                    <measurement group_id="O6" value="0.02" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.15"/>
                    <measurement group_id="O2" value="-0.01" spread="0.18"/>
                    <measurement group_id="O3" value="0.02" spread="0.15"/>
                    <measurement group_id="O4" value="0.00" spread="0.11"/>
                    <measurement group_id="O5" value="-0.02" spread="0.22"/>
                    <measurement group_id="O6" value="-0.03" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.15"/>
                    <measurement group_id="O2" value="-0.03" spread="0.11"/>
                    <measurement group_id="O3" value="0.00" spread="0.16"/>
                    <measurement group_id="O4" value="-0.01" spread="0.14"/>
                    <measurement group_id="O5" value="-0.04" spread="0.17"/>
                    <measurement group_id="O6" value="-0.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.16"/>
                    <measurement group_id="O2" value="0.00" spread="0.14"/>
                    <measurement group_id="O3" value="-0.02" spread="0.15"/>
                    <measurement group_id="O4" value="-0.01" spread="0.18"/>
                    <measurement group_id="O5" value="-0.07" spread="0.17"/>
                    <measurement group_id="O6" value="-0.01" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.22"/>
                    <measurement group_id="O2" value="0.10" spread="0.22"/>
                    <measurement group_id="O3" value="0.03" spread="0.10"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="-0.30" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.07" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.16"/>
                    <measurement group_id="O2" value="-0.55" spread="1.12"/>
                    <measurement group_id="O3" value="-0.32" spread="1.25"/>
                    <measurement group_id="O4" value="-0.81" spread="1.81"/>
                    <measurement group_id="O5" value="-0.37" spread="1.20"/>
                    <measurement group_id="O6" value="-0.44" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="1.29"/>
                    <measurement group_id="O2" value="-0.43" spread="1.05"/>
                    <measurement group_id="O3" value="-0.31" spread="1.33"/>
                    <measurement group_id="O4" value="-0.59" spread="1.09"/>
                    <measurement group_id="O5" value="-0.41" spread="1.64"/>
                    <measurement group_id="O6" value="-0.36" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.30"/>
                    <measurement group_id="O2" value="-0.35" spread="1.07"/>
                    <measurement group_id="O3" value="-0.39" spread="1.31"/>
                    <measurement group_id="O4" value="-0.68" spread="1.02"/>
                    <measurement group_id="O5" value="-0.48" spread="1.60"/>
                    <measurement group_id="O6" value="-0.40" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.98"/>
                    <measurement group_id="O2" value="-0.43" spread="1.64"/>
                    <measurement group_id="O3" value="-0.49" spread="1.38"/>
                    <measurement group_id="O4" value="-0.54" spread="1.16"/>
                    <measurement group_id="O5" value="-0.50" spread="1.78"/>
                    <measurement group_id="O6" value="-0.36" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.18"/>
                    <measurement group_id="O2" value="-0.61" spread="1.40"/>
                    <measurement group_id="O3" value="-0.34" spread="1.72"/>
                    <measurement group_id="O4" value="-0.57" spread="1.28"/>
                    <measurement group_id="O5" value="-0.45" spread="1.61"/>
                    <measurement group_id="O6" value="-0.47" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="1.17"/>
                    <measurement group_id="O2" value="-0.33" spread="1.50"/>
                    <measurement group_id="O3" value="-0.49" spread="1.50"/>
                    <measurement group_id="O4" value="-0.57" spread="1.20"/>
                    <measurement group_id="O5" value="-0.59" spread="1.28"/>
                    <measurement group_id="O6" value="-0.39" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.79"/>
                    <measurement group_id="O2" value="0.75" spread="1.88"/>
                    <measurement group_id="O3" value="0.65" spread="1.20"/>
                    <measurement group_id="O4" value="-0.95" spread="0.49"/>
                    <measurement group_id="O5" value="0.50" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.13" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Calcium, Chloride, Potassium, Magnesium, Sodium, Urea Nitrogen, Cholesterol, Glucose)</title>
        <description>Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Calcium, Chloride, Potassium, Magnesium, Sodium, Urea Nitrogen, Cholesterol, Glucose)</title>
          <description>Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.076"/>
                    <measurement group_id="O2" value="0.011" spread="0.088"/>
                    <measurement group_id="O3" value="-0.021" spread="0.126"/>
                    <measurement group_id="O4" value="-0.017" spread="0.076"/>
                    <measurement group_id="O5" value="0.000" spread="0.077"/>
                    <measurement group_id="O6" value="-0.010" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.082"/>
                    <measurement group_id="O2" value="0.034" spread="0.094"/>
                    <measurement group_id="O3" value="-0.007" spread="0.092"/>
                    <measurement group_id="O4" value="0.004" spread="0.074"/>
                    <measurement group_id="O5" value="0.006" spread="0.088"/>
                    <measurement group_id="O6" value="-0.006" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.073"/>
                    <measurement group_id="O2" value="0.012" spread="0.099"/>
                    <measurement group_id="O3" value="-0.020" spread="0.106"/>
                    <measurement group_id="O4" value="-0.008" spread="0.074"/>
                    <measurement group_id="O5" value="0.005" spread="0.099"/>
                    <measurement group_id="O6" value="-0.010" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" spread="0.070"/>
                    <measurement group_id="O2" value="0.009" spread="0.079"/>
                    <measurement group_id="O3" value="-0.019" spread="0.091"/>
                    <measurement group_id="O4" value="-0.008" spread="0.092"/>
                    <measurement group_id="O5" value="-0.026" spread="0.086"/>
                    <measurement group_id="O6" value="-0.027" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.084"/>
                    <measurement group_id="O2" value="0.001" spread="0.106"/>
                    <measurement group_id="O3" value="-0.027" spread="0.099"/>
                    <measurement group_id="O4" value="0.019" spread="0.089"/>
                    <measurement group_id="O5" value="-0.002" spread="0.089"/>
                    <measurement group_id="O6" value="-0.016" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.095"/>
                    <measurement group_id="O2" value="0.025" spread="0.092"/>
                    <measurement group_id="O3" value="-0.038" spread="0.120"/>
                    <measurement group_id="O4" value="0.001" spread="0.093"/>
                    <measurement group_id="O5" value="-0.019" spread="0.121"/>
                    <measurement group_id="O6" value="-0.001" spread="0.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.095" spread="0.083"/>
                    <measurement group_id="O2" value="-0.050" spread="0.109"/>
                    <measurement group_id="O3" value="-0.073" spread="0.045"/>
                    <measurement group_id="O4" value="-0.125" spread="0.134"/>
                    <measurement group_id="O5" value="0.020" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.020" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.8"/>
                    <measurement group_id="O2" value="0.6" spread="2.0"/>
                    <measurement group_id="O3" value="0.6" spread="2.3"/>
                    <measurement group_id="O4" value="0.6" spread="2.5"/>
                    <measurement group_id="O5" value="0.3" spread="2.1"/>
                    <measurement group_id="O6" value="0.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.3"/>
                    <measurement group_id="O2" value="0.1" spread="2.4"/>
                    <measurement group_id="O3" value="-0.3" spread="2.2"/>
                    <measurement group_id="O4" value="0.4" spread="2.3"/>
                    <measurement group_id="O5" value="0.5" spread="2.1"/>
                    <measurement group_id="O6" value="0.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.8"/>
                    <measurement group_id="O2" value="0.8" spread="2.1"/>
                    <measurement group_id="O3" value="0.0" spread="2.5"/>
                    <measurement group_id="O4" value="0.2" spread="2.3"/>
                    <measurement group_id="O5" value="-0.1" spread="2.6"/>
                    <measurement group_id="O6" value="-0.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.1"/>
                    <measurement group_id="O2" value="0.0" spread="2.3"/>
                    <measurement group_id="O3" value="-0.6" spread="1.7"/>
                    <measurement group_id="O4" value="0.0" spread="2.4"/>
                    <measurement group_id="O5" value="-0.1" spread="3.0"/>
                    <measurement group_id="O6" value="0.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.1"/>
                    <measurement group_id="O2" value="0.3" spread="2.3"/>
                    <measurement group_id="O3" value="0.3" spread="2.0"/>
                    <measurement group_id="O4" value="-0.1" spread="2.9"/>
                    <measurement group_id="O5" value="0.1" spread="2.4"/>
                    <measurement group_id="O6" value="0.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.7"/>
                    <measurement group_id="O2" value="-0.1" spread="2.5"/>
                    <measurement group_id="O3" value="-0.2" spread="2.0"/>
                    <measurement group_id="O4" value="0.2" spread="2.3"/>
                    <measurement group_id="O5" value="0.8" spread="2.4"/>
                    <measurement group_id="O6" value="0.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.6"/>
                    <measurement group_id="O2" value="3.0" spread="2.7"/>
                    <measurement group_id="O3" value="0.5" spread="5.4"/>
                    <measurement group_id="O4" value="2.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.45"/>
                    <measurement group_id="O2" value="0.08" spread="0.33"/>
                    <measurement group_id="O3" value="0.05" spread="0.41"/>
                    <measurement group_id="O4" value="0.02" spread="0.36"/>
                    <measurement group_id="O5" value="-0.03" spread="0.32"/>
                    <measurement group_id="O6" value="0.04" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.30"/>
                    <measurement group_id="O2" value="0.08" spread="0.33"/>
                    <measurement group_id="O3" value="0.02" spread="0.32"/>
                    <measurement group_id="O4" value="-0.06" spread="0.29"/>
                    <measurement group_id="O5" value="0.05" spread="0.37"/>
                    <measurement group_id="O6" value="-0.03" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.40"/>
                    <measurement group_id="O2" value="0.12" spread="0.41"/>
                    <measurement group_id="O3" value="0.09" spread="0.38"/>
                    <measurement group_id="O4" value="0.01" spread="0.34"/>
                    <measurement group_id="O5" value="0.05" spread="0.40"/>
                    <measurement group_id="O6" value="0.03" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.32"/>
                    <measurement group_id="O2" value="0.11" spread="0.35"/>
                    <measurement group_id="O3" value="-0.03" spread="0.31"/>
                    <measurement group_id="O4" value="-0.07" spread="0.33"/>
                    <measurement group_id="O5" value="-0.07" spread="0.34"/>
                    <measurement group_id="O6" value="-0.02" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.39"/>
                    <measurement group_id="O2" value="0.07" spread="0.36"/>
                    <measurement group_id="O3" value="0.12" spread="0.38"/>
                    <measurement group_id="O4" value="-0.06" spread="0.38"/>
                    <measurement group_id="O5" value="-0.12" spread="0.40"/>
                    <measurement group_id="O6" value="0.02" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.35"/>
                    <measurement group_id="O2" value="0.08" spread="0.34"/>
                    <measurement group_id="O3" value="0.08" spread="0.37"/>
                    <measurement group_id="O4" value="-0.06" spread="0.37"/>
                    <measurement group_id="O5" value="-0.07" spread="0.37"/>
                    <measurement group_id="O6" value="-0.06" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.36"/>
                    <measurement group_id="O2" value="0.10" spread="0.37"/>
                    <measurement group_id="O3" value="-0.10" spread="0.29"/>
                    <measurement group_id="O4" value="-0.45" spread="0.07"/>
                    <measurement group_id="O5" value="0.20" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.20" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.074"/>
                    <measurement group_id="O2" value="-0.002" spread="0.052"/>
                    <measurement group_id="O3" value="-0.020" spread="0.069"/>
                    <measurement group_id="O4" value="0.005" spread="0.079"/>
                    <measurement group_id="O5" value="-0.007" spread="0.077"/>
                    <measurement group_id="O6" value="-0.009" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.012" spread="0.063"/>
                    <measurement group_id="O2" value="-0.004" spread="0.064"/>
                    <measurement group_id="O3" value="-0.010" spread="0.065"/>
                    <measurement group_id="O4" value="0.001" spread="0.068"/>
                    <measurement group_id="O5" value="-0.017" spread="0.086"/>
                    <measurement group_id="O6" value="0.005" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.077"/>
                    <measurement group_id="O2" value="-0.004" spread="0.062"/>
                    <measurement group_id="O3" value="-0.017" spread="0.046"/>
                    <measurement group_id="O4" value="0.008" spread="0.071"/>
                    <measurement group_id="O5" value="-0.017" spread="0.067"/>
                    <measurement group_id="O6" value="-0.013" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.054"/>
                    <measurement group_id="O2" value="-0.014" spread="0.053"/>
                    <measurement group_id="O3" value="-0.013" spread="0.057"/>
                    <measurement group_id="O4" value="-0.008" spread="0.065"/>
                    <measurement group_id="O5" value="-0.020" spread="0.073"/>
                    <measurement group_id="O6" value="-0.017" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.026" spread="0.070"/>
                    <measurement group_id="O2" value="-0.023" spread="0.042"/>
                    <measurement group_id="O3" value="-0.023" spread="0.063"/>
                    <measurement group_id="O4" value="0.003" spread="0.071"/>
                    <measurement group_id="O5" value="-0.019" spread="0.072"/>
                    <measurement group_id="O6" value="-0.021" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.093"/>
                    <measurement group_id="O2" value="0.007" spread="0.074"/>
                    <measurement group_id="O3" value="-0.025" spread="0.069"/>
                    <measurement group_id="O4" value="0.009" spread="0.074"/>
                    <measurement group_id="O5" value="-0.017" spread="0.075"/>
                    <measurement group_id="O6" value="-0.008" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.093"/>
                    <measurement group_id="O2" value="0.110" spread="0.295"/>
                    <measurement group_id="O3" value="-0.035" spread="0.047"/>
                    <measurement group_id="O4" value="-0.050" spread="0.057"/>
                    <measurement group_id="O5" value="-0.060" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.023" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.8"/>
                    <measurement group_id="O2" value="0.2" spread="1.7"/>
                    <measurement group_id="O3" value="0.3" spread="2.7"/>
                    <measurement group_id="O4" value="0.1" spread="1.9"/>
                    <measurement group_id="O5" value="0.0" spread="2.2"/>
                    <measurement group_id="O6" value="0.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.7"/>
                    <measurement group_id="O2" value="-0.2" spread="1.4"/>
                    <measurement group_id="O3" value="-0.4" spread="1.8"/>
                    <measurement group_id="O4" value="0.0" spread="2.0"/>
                    <measurement group_id="O5" value="0.2" spread="2.3"/>
                    <measurement group_id="O6" value="0.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.7"/>
                    <measurement group_id="O2" value="0.2" spread="1.7"/>
                    <measurement group_id="O3" value="0.2" spread="1.7"/>
                    <measurement group_id="O4" value="-0.2" spread="1.7"/>
                    <measurement group_id="O5" value="-0.1" spread="2.3"/>
                    <measurement group_id="O6" value="-0.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.0"/>
                    <measurement group_id="O2" value="-0.1" spread="2.1"/>
                    <measurement group_id="O3" value="-0.8" spread="1.6"/>
                    <measurement group_id="O4" value="-0.1" spread="1.9"/>
                    <measurement group_id="O5" value="-0.1" spread="2.9"/>
                    <measurement group_id="O6" value="-0.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.0"/>
                    <measurement group_id="O2" value="0.0" spread="2.8"/>
                    <measurement group_id="O3" value="-0.2" spread="1.8"/>
                    <measurement group_id="O4" value="-0.2" spread="2.0"/>
                    <measurement group_id="O5" value="-0.1" spread="2.2"/>
                    <measurement group_id="O6" value="-0.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.0"/>
                    <measurement group_id="O2" value="-0.2" spread="1.7"/>
                    <measurement group_id="O3" value="-0.1" spread="1.7"/>
                    <measurement group_id="O4" value="-0.2" spread="2.0"/>
                    <measurement group_id="O5" value="-0.2" spread="2.4"/>
                    <measurement group_id="O6" value="-0.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.1"/>
                    <measurement group_id="O2" value="0.8" spread="1.7"/>
                    <measurement group_id="O3" value="-2.0" spread="2.2"/>
                    <measurement group_id="O4" value="-2.0" spread="2.8"/>
                    <measurement group_id="O5" value="-1.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.09"/>
                    <measurement group_id="O2" value="0.11" spread="1.12"/>
                    <measurement group_id="O3" value="0.27" spread="1.19"/>
                    <measurement group_id="O4" value="0.34" spread="1.22"/>
                    <measurement group_id="O5" value="0.27" spread="1.24"/>
                    <measurement group_id="O6" value="0.21" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="1.16"/>
                    <measurement group_id="O2" value="-0.03" spread="1.25"/>
                    <measurement group_id="O3" value="0.24" spread="1.16"/>
                    <measurement group_id="O4" value="0.16" spread="1.17"/>
                    <measurement group_id="O5" value="0.27" spread="1.17"/>
                    <measurement group_id="O6" value="0.37" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="1.16"/>
                    <measurement group_id="O2" value="0.48" spread="1.52"/>
                    <measurement group_id="O3" value="0.50" spread="1.31"/>
                    <measurement group_id="O4" value="-0.03" spread="1.20"/>
                    <measurement group_id="O5" value="-0.11" spread="1.08"/>
                    <measurement group_id="O6" value="0.15" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.96"/>
                    <measurement group_id="O2" value="0.21" spread="1.40"/>
                    <measurement group_id="O3" value="0.41" spread="1.14"/>
                    <measurement group_id="O4" value="0.19" spread="1.31"/>
                    <measurement group_id="O5" value="0.29" spread="1.14"/>
                    <measurement group_id="O6" value="0.12" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="1.29"/>
                    <measurement group_id="O2" value="0.14" spread="1.33"/>
                    <measurement group_id="O3" value="0.32" spread="1.08"/>
                    <measurement group_id="O4" value="-0.08" spread="1.58"/>
                    <measurement group_id="O5" value="0.33" spread="1.30"/>
                    <measurement group_id="O6" value="0.35" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.35"/>
                    <measurement group_id="O2" value="-0.04" spread="1.37"/>
                    <measurement group_id="O3" value="0.39" spread="1.14"/>
                    <measurement group_id="O4" value="0.08" spread="1.13"/>
                    <measurement group_id="O5" value="0.13" spread="1.08"/>
                    <measurement group_id="O6" value="0.01" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.74"/>
                    <measurement group_id="O2" value="0.80" spread="1.19"/>
                    <measurement group_id="O3" value="0.78" spread="3.27"/>
                    <measurement group_id="O4" value="-0.65" spread="2.05"/>
                    <measurement group_id="O5" value="-0.30" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.77" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.47"/>
                    <measurement group_id="O2" value="-0.06" spread="0.54"/>
                    <measurement group_id="O3" value="0.00" spread="0.65"/>
                    <measurement group_id="O4" value="-0.09" spread="0.59"/>
                    <measurement group_id="O5" value="0.12" spread="0.65"/>
                    <measurement group_id="O6" value="0.06" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.71"/>
                    <measurement group_id="O2" value="0.03" spread="0.63"/>
                    <measurement group_id="O3" value="0.12" spread="0.58"/>
                    <measurement group_id="O4" value="-0.11" spread="0.52"/>
                    <measurement group_id="O5" value="0.12" spread="1.04"/>
                    <measurement group_id="O6" value="0.05" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.59"/>
                    <measurement group_id="O2" value="0.04" spread="0.63"/>
                    <measurement group_id="O3" value="0.17" spread="0.55"/>
                    <measurement group_id="O4" value="-0.31" spread="0.88"/>
                    <measurement group_id="O5" value="0.00" spread="1.30"/>
                    <measurement group_id="O6" value="0.05" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.46"/>
                    <measurement group_id="O2" value="-0.02" spread="0.73"/>
                    <measurement group_id="O3" value="0.17" spread="0.56"/>
                    <measurement group_id="O4" value="-0.24" spread="0.70"/>
                    <measurement group_id="O5" value="-0.24" spread="1.32"/>
                    <measurement group_id="O6" value="0.08" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.67"/>
                    <measurement group_id="O2" value="-0.17" spread="0.68"/>
                    <measurement group_id="O3" value="0.16" spread="0.64"/>
                    <measurement group_id="O4" value="-0.13" spread="0.83"/>
                    <measurement group_id="O5" value="-0.17" spread="1.22"/>
                    <measurement group_id="O6" value="0.01" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.88"/>
                    <measurement group_id="O2" value="-0.07" spread="0.62"/>
                    <measurement group_id="O3" value="0.11" spread="0.62"/>
                    <measurement group_id="O4" value="-0.18" spread="0.77"/>
                    <measurement group_id="O5" value="0.01" spread="1.29"/>
                    <measurement group_id="O6" value="-0.05" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.30"/>
                    <measurement group_id="O2" value="-0.83" spread="1.56"/>
                    <measurement group_id="O3" value="0.38" spread="0.52"/>
                    <measurement group_id="O4" value="-0.80" spread="0.14"/>
                    <measurement group_id="O5" value="0.20" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.40" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="1.59"/>
                    <measurement group_id="O2" value="0.12" spread="0.82"/>
                    <measurement group_id="O3" value="-0.14" spread="1.00"/>
                    <measurement group_id="O4" value="-0.06" spread="1.14"/>
                    <measurement group_id="O5" value="0.07" spread="1.10"/>
                    <measurement group_id="O6" value="0.22" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="1.62"/>
                    <measurement group_id="O2" value="0.17" spread="1.23"/>
                    <measurement group_id="O3" value="-0.05" spread="0.92"/>
                    <measurement group_id="O4" value="-0.20" spread="1.13"/>
                    <measurement group_id="O5" value="0.03" spread="1.09"/>
                    <measurement group_id="O6" value="0.05" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="1.42"/>
                    <measurement group_id="O2" value="0.25" spread="1.22"/>
                    <measurement group_id="O3" value="-0.12" spread="1.03"/>
                    <measurement group_id="O4" value="-0.09" spread="1.24"/>
                    <measurement group_id="O5" value="0.37" spread="1.20"/>
                    <measurement group_id="O6" value="0.19" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.42"/>
                    <measurement group_id="O2" value="0.30" spread="1.15"/>
                    <measurement group_id="O3" value="-0.04" spread="1.26"/>
                    <measurement group_id="O4" value="0.02" spread="1.60"/>
                    <measurement group_id="O5" value="0.21" spread="1.30"/>
                    <measurement group_id="O6" value="0.29" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="1.48"/>
                    <measurement group_id="O2" value="0.22" spread="1.48"/>
                    <measurement group_id="O3" value="-0.15" spread="0.87"/>
                    <measurement group_id="O4" value="-0.06" spread="1.43"/>
                    <measurement group_id="O5" value="0.11" spread="1.10"/>
                    <measurement group_id="O6" value="0.03" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="1.27"/>
                    <measurement group_id="O2" value="0.01" spread="1.08"/>
                    <measurement group_id="O3" value="0.02" spread="1.35"/>
                    <measurement group_id="O4" value="-0.17" spread="1.23"/>
                    <measurement group_id="O5" value="-0.15" spread="0.88"/>
                    <measurement group_id="O6" value="0.04" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.48"/>
                    <measurement group_id="O2" value="0.75" spread="0.89"/>
                    <measurement group_id="O3" value="-0.33" spread="0.67"/>
                    <measurement group_id="O4" value="-0.25" spread="0.49"/>
                    <measurement group_id="O5" value="0.20" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.17" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Lactate Dehydrogenase, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase)</title>
        <description>Lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase were measured in units per liter (U/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Lactate Dehydrogenase, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase)</title>
          <description>Lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase were measured in units per liter (U/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lactate Dehydrogenase Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="29.4"/>
                    <measurement group_id="O2" value="1.1" spread="24.8"/>
                    <measurement group_id="O3" value="-5.0" spread="24.1"/>
                    <measurement group_id="O4" value="-0.3" spread="21.4"/>
                    <measurement group_id="O5" value="-4.6" spread="18.9"/>
                    <measurement group_id="O6" value="-3.4" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="26.4"/>
                    <measurement group_id="O2" value="-2.5" spread="25.2"/>
                    <measurement group_id="O3" value="-3.5" spread="22.1"/>
                    <measurement group_id="O4" value="0.4" spread="27.6"/>
                    <measurement group_id="O5" value="-7.6" spread="27.4"/>
                    <measurement group_id="O6" value="-5.1" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="22.4"/>
                    <measurement group_id="O2" value="1.7" spread="31.9"/>
                    <measurement group_id="O3" value="-8.1" spread="16.7"/>
                    <measurement group_id="O4" value="5.0" spread="43.5"/>
                    <measurement group_id="O5" value="-4.5" spread="37.7"/>
                    <measurement group_id="O6" value="-4.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="27.7"/>
                    <measurement group_id="O2" value="-1.4" spread="25.2"/>
                    <measurement group_id="O3" value="-7.3" spread="20.3"/>
                    <measurement group_id="O4" value="2.0" spread="16.2"/>
                    <measurement group_id="O5" value="-11.0" spread="27.5"/>
                    <measurement group_id="O6" value="-3.5" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="27.4"/>
                    <measurement group_id="O2" value="0.5" spread="25.2"/>
                    <measurement group_id="O3" value="-12.3" spread="22.2"/>
                    <measurement group_id="O4" value="-0.8" spread="18.9"/>
                    <measurement group_id="O5" value="-10.7" spread="33.1"/>
                    <measurement group_id="O6" value="-3.7" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="28.1"/>
                    <measurement group_id="O2" value="2.9" spread="26.7"/>
                    <measurement group_id="O3" value="-7.5" spread="25.1"/>
                    <measurement group_id="O4" value="-0.3" spread="20.6"/>
                    <measurement group_id="O5" value="-5.6" spread="33.1"/>
                    <measurement group_id="O6" value="-4.4" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="12.9"/>
                    <measurement group_id="O2" value="-5.0" spread="18.4"/>
                    <measurement group_id="O3" value="3.3" spread="81.2"/>
                    <measurement group_id="O4" value="-45.5" spread="16.3"/>
                    <measurement group_id="O5" value="15.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="32.3" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="6.3"/>
                    <measurement group_id="O2" value="-0.5" spread="6.0"/>
                    <measurement group_id="O3" value="-3.5" spread="8.2"/>
                    <measurement group_id="O4" value="-3.8" spread="7.7"/>
                    <measurement group_id="O5" value="-1.9" spread="5.3"/>
                    <measurement group_id="O6" value="-2.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="12.7"/>
                    <measurement group_id="O2" value="0.0" spread="7.4"/>
                    <measurement group_id="O3" value="-2.5" spread="10.5"/>
                    <measurement group_id="O4" value="-2.7" spread="8.2"/>
                    <measurement group_id="O5" value="-1.6" spread="6.5"/>
                    <measurement group_id="O6" value="-1.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="8.7"/>
                    <measurement group_id="O2" value="-1.9" spread="9.2"/>
                    <measurement group_id="O3" value="-6.2" spread="9.8"/>
                    <measurement group_id="O4" value="-4.3" spread="9.4"/>
                    <measurement group_id="O5" value="-2.6" spread="8.1"/>
                    <measurement group_id="O6" value="-1.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="8.3"/>
                    <measurement group_id="O2" value="-1.8" spread="9.0"/>
                    <measurement group_id="O3" value="-5.5" spread="10.0"/>
                    <measurement group_id="O4" value="-2.4" spread="8.6"/>
                    <measurement group_id="O5" value="-2.1" spread="9.6"/>
                    <measurement group_id="O6" value="-1.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="12.2"/>
                    <measurement group_id="O2" value="-1.7" spread="8.0"/>
                    <measurement group_id="O3" value="-4.2" spread="11.2"/>
                    <measurement group_id="O4" value="-2.1" spread="10.0"/>
                    <measurement group_id="O5" value="-1.1" spread="11.3"/>
                    <measurement group_id="O6" value="-1.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="8.1"/>
                    <measurement group_id="O2" value="0.3" spread="7.2"/>
                    <measurement group_id="O3" value="-2.4" spread="11.8"/>
                    <measurement group_id="O4" value="-0.4" spread="9.0"/>
                    <measurement group_id="O5" value="-0.5" spread="10.4"/>
                    <measurement group_id="O6" value="-0.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="7.4"/>
                    <measurement group_id="O2" value="9.8" spread="8.9"/>
                    <measurement group_id="O3" value="7.8" spread="15.3"/>
                    <measurement group_id="O4" value="-3.0" spread="5.7"/>
                    <measurement group_id="O5" value="3.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="7.7"/>
                    <measurement group_id="O2" value="2.1" spread="10.4"/>
                    <measurement group_id="O3" value="-1.7" spread="13.7"/>
                    <measurement group_id="O4" value="1.6" spread="12.2"/>
                    <measurement group_id="O5" value="0.7" spread="8.9"/>
                    <measurement group_id="O6" value="1.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.5"/>
                    <measurement group_id="O2" value="1.9" spread="9.0"/>
                    <measurement group_id="O3" value="2.0" spread="29.8"/>
                    <measurement group_id="O4" value="-0.9" spread="7.7"/>
                    <measurement group_id="O5" value="-0.2" spread="10.2"/>
                    <measurement group_id="O6" value="1.6" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="7.0"/>
                    <measurement group_id="O2" value="1.1" spread="8.6"/>
                    <measurement group_id="O3" value="0.8" spread="18.7"/>
                    <measurement group_id="O4" value="-0.4" spread="10.2"/>
                    <measurement group_id="O5" value="0.4" spread="14.7"/>
                    <measurement group_id="O6" value="1.0" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="18.9"/>
                    <measurement group_id="O2" value="1.1" spread="8.9"/>
                    <measurement group_id="O3" value="-0.6" spread="11.7"/>
                    <measurement group_id="O4" value="3.5" spread="20.9"/>
                    <measurement group_id="O5" value="-1.7" spread="13.7"/>
                    <measurement group_id="O6" value="1.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="10.8"/>
                    <measurement group_id="O2" value="2.2" spread="10.2"/>
                    <measurement group_id="O3" value="0.1" spread="10.5"/>
                    <measurement group_id="O4" value="-0.4" spread="9.7"/>
                    <measurement group_id="O5" value="-1.1" spread="14.5"/>
                    <measurement group_id="O6" value="0.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="7.5"/>
                    <measurement group_id="O2" value="1.8" spread="9.9"/>
                    <measurement group_id="O3" value="-1.0" spread="10.8"/>
                    <measurement group_id="O4" value="-0.9" spread="9.1"/>
                    <measurement group_id="O5" value="-0.9" spread="14.6"/>
                    <measurement group_id="O6" value="-0.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.0"/>
                    <measurement group_id="O2" value="4.3" spread="3.4"/>
                    <measurement group_id="O3" value="26.5" spread="42.1"/>
                    <measurement group_id="O4" value="-6.0" spread="8.5"/>
                    <measurement group_id="O5" value="16.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-3.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="6.1"/>
                    <measurement group_id="O2" value="2.0" spread="10.8"/>
                    <measurement group_id="O3" value="-3.0" spread="15.2"/>
                    <measurement group_id="O4" value="1.9" spread="11.5"/>
                    <measurement group_id="O5" value="0.3" spread="6.3"/>
                    <measurement group_id="O6" value="-0.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.8"/>
                    <measurement group_id="O2" value="0.4" spread="4.9"/>
                    <measurement group_id="O3" value="-1.9" spread="19.1"/>
                    <measurement group_id="O4" value="-0.9" spread="4.7"/>
                    <measurement group_id="O5" value="-0.5" spread="6.1"/>
                    <measurement group_id="O6" value="0.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="4.8"/>
                    <measurement group_id="O2" value="-0.1" spread="5.8"/>
                    <measurement group_id="O3" value="-2.5" spread="17.5"/>
                    <measurement group_id="O4" value="-0.4" spread="5.9"/>
                    <measurement group_id="O5" value="0.6" spread="8.2"/>
                    <measurement group_id="O6" value="-0.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="10.6"/>
                    <measurement group_id="O2" value="0.8" spread="6.0"/>
                    <measurement group_id="O3" value="-0.9" spread="9.5"/>
                    <measurement group_id="O4" value="4.0" spread="15.7"/>
                    <measurement group_id="O5" value="-1.4" spread="7.0"/>
                    <measurement group_id="O6" value="-1.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="5.1"/>
                    <measurement group_id="O2" value="0.2" spread="6.7"/>
                    <measurement group_id="O3" value="-1.4" spread="5.4"/>
                    <measurement group_id="O4" value="-1.4" spread="4.6"/>
                    <measurement group_id="O5" value="-0.4" spread="8.3"/>
                    <measurement group_id="O6" value="-0.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="5.5"/>
                    <measurement group_id="O2" value="1.1" spread="7.9"/>
                    <measurement group_id="O3" value="-1.4" spread="8.3"/>
                    <measurement group_id="O4" value="-0.3" spread="4.8"/>
                    <measurement group_id="O5" value="-0.5" spread="7.3"/>
                    <measurement group_id="O6" value="-0.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.7"/>
                    <measurement group_id="O2" value="-0.3" spread="2.1"/>
                    <measurement group_id="O3" value="11.5" spread="23.5"/>
                    <measurement group_id="O4" value="-4.0" spread="2.8"/>
                    <measurement group_id="O5" value="9.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="6.4"/>
                    <measurement group_id="O2" value="-0.8" spread="14.1"/>
                    <measurement group_id="O3" value="-2.0" spread="10.7"/>
                    <measurement group_id="O4" value="-7.5" spread="42.1"/>
                    <measurement group_id="O5" value="1.6" spread="22.9"/>
                    <measurement group_id="O6" value="-0.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="8.7"/>
                    <measurement group_id="O2" value="-1.6" spread="11.1"/>
                    <measurement group_id="O3" value="0.2" spread="14.2"/>
                    <measurement group_id="O4" value="-1.2" spread="8.0"/>
                    <measurement group_id="O5" value="-1.9" spread="6.5"/>
                    <measurement group_id="O6" value="0.4" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="8.5"/>
                    <measurement group_id="O2" value="-1.9" spread="11.8"/>
                    <measurement group_id="O3" value="1.8" spread="18.6"/>
                    <measurement group_id="O4" value="-2.6" spread="12.8"/>
                    <measurement group_id="O5" value="-0.4" spread="8.4"/>
                    <measurement group_id="O6" value="-1.4" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="10.5"/>
                    <measurement group_id="O2" value="-1.8" spread="13.8"/>
                    <measurement group_id="O3" value="-2.9" spread="13.1"/>
                    <measurement group_id="O4" value="-2.9" spread="7.3"/>
                    <measurement group_id="O5" value="-2.1" spread="9.3"/>
                    <measurement group_id="O6" value="-1.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="13.7"/>
                    <measurement group_id="O2" value="-1.9" spread="14.9"/>
                    <measurement group_id="O3" value="-0.9" spread="18.4"/>
                    <measurement group_id="O4" value="-2.6" spread="13.6"/>
                    <measurement group_id="O5" value="-2.5" spread="9.4"/>
                    <measurement group_id="O6" value="3.1" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="10.9"/>
                    <measurement group_id="O2" value="-2.2" spread="13.3"/>
                    <measurement group_id="O3" value="-1.1" spread="21.7"/>
                    <measurement group_id="O4" value="-0.6" spread="11.2"/>
                    <measurement group_id="O5" value="-0.4" spread="11.1"/>
                    <measurement group_id="O6" value="-0.9" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="13.4"/>
                    <measurement group_id="O2" value="1.3" spread="3.9"/>
                    <measurement group_id="O3" value="19.8" spread="23.3"/>
                    <measurement group_id="O4" value="-16.5" spread="24.7"/>
                    <measurement group_id="O5" value="37.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="3.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin)</title>
        <description>Creatinine and bilirubin were measured in micromols per liter (μmol/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin)</title>
          <description>Creatinine and bilirubin were measured in micromols per liter (μmol/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="7.0"/>
                    <measurement group_id="O2" value="2.7" spread="10.1"/>
                    <measurement group_id="O3" value="1.4" spread="8.6"/>
                    <measurement group_id="O4" value="0.6" spread="8.1"/>
                    <measurement group_id="O5" value="0.7" spread="8.4"/>
                    <measurement group_id="O6" value="-0.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="7.1"/>
                    <measurement group_id="O2" value="-0.8" spread="8.2"/>
                    <measurement group_id="O3" value="-0.4" spread="10.1"/>
                    <measurement group_id="O4" value="-0.7" spread="8.5"/>
                    <measurement group_id="O5" value="-0.1" spread="8.3"/>
                    <measurement group_id="O6" value="0.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="5.8"/>
                    <measurement group_id="O2" value="1.3" spread="9.1"/>
                    <measurement group_id="O3" value="0.6" spread="7.9"/>
                    <measurement group_id="O4" value="-1.7" spread="8.1"/>
                    <measurement group_id="O5" value="0.6" spread="8.1"/>
                    <measurement group_id="O6" value="1.6" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="7.8"/>
                    <measurement group_id="O2" value="1.6" spread="10.5"/>
                    <measurement group_id="O3" value="-0.1" spread="10.6"/>
                    <measurement group_id="O4" value="-0.6" spread="7.9"/>
                    <measurement group_id="O5" value="-0.1" spread="8.1"/>
                    <measurement group_id="O6" value="-0.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="6.2"/>
                    <measurement group_id="O2" value="-0.4" spread="7.4"/>
                    <measurement group_id="O3" value="-1.0" spread="9.6"/>
                    <measurement group_id="O4" value="-2.6" spread="8.4"/>
                    <measurement group_id="O5" value="-0.1" spread="7.6"/>
                    <measurement group_id="O6" value="0.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="7.8"/>
                    <measurement group_id="O2" value="-0.2" spread="7.0"/>
                    <measurement group_id="O3" value="0.7" spread="12.0"/>
                    <measurement group_id="O4" value="-0.7" spread="9.1"/>
                    <measurement group_id="O5" value="0.1" spread="9.0"/>
                    <measurement group_id="O6" value="-0.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.4"/>
                    <measurement group_id="O2" value="6.0" spread="4.3"/>
                    <measurement group_id="O3" value="-6.5" spread="4.4"/>
                    <measurement group_id="O4" value="-10.5" spread="16.3"/>
                    <measurement group_id="O5" value="9.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="1.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="3.10"/>
                    <measurement group_id="O2" value="-1.79" spread="4.50"/>
                    <measurement group_id="O3" value="-0.52" spread="2.81"/>
                    <measurement group_id="O4" value="-0.55" spread="4.49"/>
                    <measurement group_id="O5" value="0.57" spread="5.73"/>
                    <measurement group_id="O6" value="0.14" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="2.85"/>
                    <measurement group_id="O2" value="-0.86" spread="5.05"/>
                    <measurement group_id="O3" value="-0.48" spread="3.40"/>
                    <measurement group_id="O4" value="-0.38" spread="3.60"/>
                    <measurement group_id="O5" value="-0.99" spread="2.98"/>
                    <measurement group_id="O6" value="0.27" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="3.26"/>
                    <measurement group_id="O2" value="-1.70" spread="4.92"/>
                    <measurement group_id="O3" value="-0.26" spread="3.53"/>
                    <measurement group_id="O4" value="-0.04" spread="2.74"/>
                    <measurement group_id="O5" value="0.76" spread="4.27"/>
                    <measurement group_id="O6" value="0.70" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="3.13"/>
                    <measurement group_id="O2" value="-1.15" spread="4.59"/>
                    <measurement group_id="O3" value="0.35" spread="3.44"/>
                    <measurement group_id="O4" value="-0.33" spread="3.94"/>
                    <measurement group_id="O5" value="0.11" spread="4.19"/>
                    <measurement group_id="O6" value="-0.30" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="3.81"/>
                    <measurement group_id="O2" value="-0.98" spread="4.68"/>
                    <measurement group_id="O3" value="-0.30" spread="3.20"/>
                    <measurement group_id="O4" value="-0.43" spread="4.52"/>
                    <measurement group_id="O5" value="-0.15" spread="3.79"/>
                    <measurement group_id="O6" value="-0.02" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="3.43"/>
                    <measurement group_id="O2" value="-1.02" spread="5.24"/>
                    <measurement group_id="O3" value="-0.73" spread="2.98"/>
                    <measurement group_id="O4" value="-1.20" spread="3.37"/>
                    <measurement group_id="O5" value="-0.43" spread="3.68"/>
                    <measurement group_id="O6" value="-0.34" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="2.16"/>
                    <measurement group_id="O2" value="-1.23" spread="2.62"/>
                    <measurement group_id="O3" value="-0.30" spread="3.87"/>
                    <measurement group_id="O4" value="-0.25" spread="0.78"/>
                    <measurement group_id="O5" value="-1.50" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="1.40" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein)</title>
        <description>C Reactive Protein was measured in milligrams per liters (mg/L).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein)</title>
          <description>C Reactive Protein was measured in milligrams per liters (mg/L).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.110" spread="5.255"/>
                    <measurement group_id="O2" value="-5.367" spread="11.806"/>
                    <measurement group_id="O3" value="-0.775" spread="2.020"/>
                    <measurement group_id="O4" value="-2.635" spread="2.550"/>
                    <measurement group_id="O5" value="-5.108" spread="10.013"/>
                    <measurement group_id="O6" value="-3.732" spread="3.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.821" spread="6.974"/>
                    <measurement group_id="O2" value="-6.985" spread="11.064"/>
                    <measurement group_id="O3" value="0.576" spread="2.898"/>
                    <measurement group_id="O4" value="2.743" spread="15.212"/>
                    <measurement group_id="O5" value="-6.763" spread="13.211"/>
                    <measurement group_id="O6" value="-3.042" spread="1.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.338" spread="11.182"/>
                    <measurement group_id="O2" value="-5.835" spread="8.594"/>
                    <measurement group_id="O3" value="-1.722" spread="5.596"/>
                    <measurement group_id="O4" value="0.929" spread="8.047"/>
                    <measurement group_id="O5" value="-4.226" spread="9.865"/>
                    <measurement group_id="O6" value="7.141" spread="32.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.978" spread="13.162"/>
                    <measurement group_id="O2" value="-5.930" spread="9.560"/>
                    <measurement group_id="O3" value="-4.516" spread="11.304"/>
                    <measurement group_id="O4" value="-0.595" spread="7.346"/>
                    <measurement group_id="O5" value="1.799" spread="14.635"/>
                    <measurement group_id="O6" value="-6.598" spread="6.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.153" spread="18.764"/>
                    <measurement group_id="O2" value="-6.891" spread="15.192"/>
                    <measurement group_id="O3" value="-3.143" spread="10.844"/>
                    <measurement group_id="O4" value="2.590" spread="7.755"/>
                    <measurement group_id="O5" value="12.434" spread="47.447"/>
                    <measurement group_id="O6" value="-1.104" spread="5.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.279" spread="13.546"/>
                    <measurement group_id="O2" value="-5.193" spread="10.817"/>
                    <measurement group_id="O3" value="0.695" spread="6.381"/>
                    <measurement group_id="O4" value="-3.033" spread="7.261"/>
                    <measurement group_id="O5" value="-9.890" spread="10.729"/>
                    <measurement group_id="O6" value="-5.368" spread="5.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (pH)</title>
        <description>Urine pH was measured on a pH scale.</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (pH)</title>
          <description>Urine pH was measured on a pH scale.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>ph</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.79"/>
                    <measurement group_id="O2" value="-0.10" spread="0.79"/>
                    <measurement group_id="O3" value="-0.13" spread="0.88"/>
                    <measurement group_id="O4" value="-0.20" spread="0.88"/>
                    <measurement group_id="O5" value="-0.08" spread="0.82"/>
                    <measurement group_id="O6" value="-0.07" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.86"/>
                    <measurement group_id="O2" value="-0.06" spread="0.86"/>
                    <measurement group_id="O3" value="-0.10" spread="0.77"/>
                    <measurement group_id="O4" value="-0.23" spread="0.92"/>
                    <measurement group_id="O5" value="-0.18" spread="0.76"/>
                    <measurement group_id="O6" value="0.06" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.87"/>
                    <measurement group_id="O2" value="-0.09" spread="0.76"/>
                    <measurement group_id="O3" value="-0.11" spread="0.95"/>
                    <measurement group_id="O4" value="-0.26" spread="0.89"/>
                    <measurement group_id="O5" value="-0.07" spread="0.73"/>
                    <measurement group_id="O6" value="-0.04" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.73"/>
                    <measurement group_id="O2" value="-0.03" spread="0.68"/>
                    <measurement group_id="O3" value="-0.17" spread="0.69"/>
                    <measurement group_id="O4" value="-0.18" spread="0.86"/>
                    <measurement group_id="O5" value="-0.13" spread="0.81"/>
                    <measurement group_id="O6" value="0.05" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.92"/>
                    <measurement group_id="O2" value="-0.07" spread="0.83"/>
                    <measurement group_id="O3" value="-0.12" spread="1.07"/>
                    <measurement group_id="O4" value="-0.34" spread="0.79"/>
                    <measurement group_id="O5" value="-0.30" spread="0.91"/>
                    <measurement group_id="O6" value="0.08" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.79"/>
                    <measurement group_id="O2" value="-0.01" spread="0.85"/>
                    <measurement group_id="O3" value="0.01" spread="0.70"/>
                    <measurement group_id="O4" value="-0.28" spread="0.85"/>
                    <measurement group_id="O5" value="-0.21" spread="0.99"/>
                    <measurement group_id="O6" value="-0.01" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="1.04"/>
                    <measurement group_id="O2" value="-0.25" spread="0.87"/>
                    <measurement group_id="O3" value="0.50" spread="1.22"/>
                    <measurement group_id="O4" value="-1.00" spread="1.41"/>
                    <measurement group_id="O5" value="0.50" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-0.17" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Leukocyte Esterase)</title>
        <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
        <time_frame>From Baseline (Week 0) until Week 12</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Leukocyte Esterase)</title>
          <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Low - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="84.2"/>
                    <measurement group_id="O3" value="97.3"/>
                    <measurement group_id="O4" value="88.2"/>
                    <measurement group_id="O5" value="90.0"/>
                    <measurement group_id="O6" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="5.9"/>
                    <measurement group_id="O5" value="5.0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="5.0"/>
                    <measurement group_id="O6" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Nitrite)</title>
        <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
        <time_frame>From Baseline (Week 0) until Week 12</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Nitrite)</title>
          <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Low - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                    <measurement group_id="O2" value="97.4"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="95.0"/>
                    <measurement group_id="O6" value="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Occult Blood)</title>
        <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
        <time_frame>From Baseline (Week 0) until Week 12</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Occult Blood)</title>
          <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Low - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="86.8"/>
                    <measurement group_id="O3" value="83.8"/>
                    <measurement group_id="O4" value="79.4"/>
                    <measurement group_id="O5" value="77.5"/>
                    <measurement group_id="O6" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5.9"/>
                    <measurement group_id="O5" value="5.0"/>
                    <measurement group_id="O6" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="8.8"/>
                    <measurement group_id="O5" value="15.0"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="5.9"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Urine Glucose)</title>
        <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
        <time_frame>From Baseline (Week 0) until Week 12</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Urine Glucose)</title>
          <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Low - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9"/>
                    <measurement group_id="O2" value="94.7"/>
                    <measurement group_id="O3" value="97.3"/>
                    <measurement group_id="O4" value="97.1"/>
                    <measurement group_id="O5" value="95.0"/>
                    <measurement group_id="O6" value="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Albumin)</title>
        <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
        <time_frame>From Baseline (Week 0) until Week 12</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Albumin)</title>
          <description>Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.&#xD;
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Low - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Low - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9"/>
                    <measurement group_id="O2" value="89.5"/>
                    <measurement group_id="O3" value="86.5"/>
                    <measurement group_id="O4" value="91.2"/>
                    <measurement group_id="O5" value="95.0"/>
                    <measurement group_id="O6" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Normal - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.9"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="5.9"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline High - Week 12 High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)</title>
        <description>Blood pressure was measured in millimeters of mercury (mmHg).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)</title>
          <description>Blood pressure was measured in millimeters of mercury (mmHg).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="10.7"/>
                    <measurement group_id="O2" value="2.2" spread="7.1"/>
                    <measurement group_id="O3" value="-3.9" spread="8.3"/>
                    <measurement group_id="O4" value="1.7" spread="9.3"/>
                    <measurement group_id="O5" value="0.2" spread="12.1"/>
                    <measurement group_id="O6" value="-1.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="9.7"/>
                    <measurement group_id="O2" value="2.1" spread="9.4"/>
                    <measurement group_id="O3" value="-2.7" spread="12.5"/>
                    <measurement group_id="O4" value="0.2" spread="13.6"/>
                    <measurement group_id="O5" value="-0.6" spread="8.4"/>
                    <measurement group_id="O6" value="-3.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="10.0"/>
                    <measurement group_id="O2" value="2.1" spread="7.9"/>
                    <measurement group_id="O3" value="-1.9" spread="11.3"/>
                    <measurement group_id="O4" value="0.1" spread="12.4"/>
                    <measurement group_id="O5" value="-0.1" spread="11.3"/>
                    <measurement group_id="O6" value="-0.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="9.8"/>
                    <measurement group_id="O2" value="-1.3" spread="10.7"/>
                    <measurement group_id="O3" value="-4.3" spread="10.6"/>
                    <measurement group_id="O4" value="0.1" spread="12.8"/>
                    <measurement group_id="O5" value="-0.9" spread="10.9"/>
                    <measurement group_id="O6" value="-2.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="12.1"/>
                    <measurement group_id="O2" value="-1.3" spread="13.0"/>
                    <measurement group_id="O3" value="-3.4" spread="8.0"/>
                    <measurement group_id="O4" value="0.1" spread="12.3"/>
                    <measurement group_id="O5" value="0.5" spread="12.5"/>
                    <measurement group_id="O6" value="-1.0" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="10.9"/>
                    <measurement group_id="O2" value="2.2" spread="9.0"/>
                    <measurement group_id="O3" value="-2.9" spread="10.3"/>
                    <measurement group_id="O4" value="-0.3" spread="11.8"/>
                    <measurement group_id="O5" value="-1.2" spread="10.4"/>
                    <measurement group_id="O6" value="-2.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="12.7"/>
                    <measurement group_id="O2" value="-10.5" spread="17.0"/>
                    <measurement group_id="O3" value="-1.3" spread="10.4"/>
                    <measurement group_id="O4" value="4.5" spread="7.8"/>
                    <measurement group_id="O5" value="-2.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-2.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="7.4"/>
                    <measurement group_id="O2" value="0.9" spread="10.0"/>
                    <measurement group_id="O3" value="-2.1" spread="7.3"/>
                    <measurement group_id="O4" value="0.6" spread="6.5"/>
                    <measurement group_id="O5" value="0.3" spread="7.4"/>
                    <measurement group_id="O6" value="0.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="6.9"/>
                    <measurement group_id="O2" value="0.4" spread="8.7"/>
                    <measurement group_id="O3" value="-1.2" spread="7.1"/>
                    <measurement group_id="O4" value="2.1" spread="8.3"/>
                    <measurement group_id="O5" value="0.0" spread="7.2"/>
                    <measurement group_id="O6" value="0.2" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.8"/>
                    <measurement group_id="O2" value="0.6" spread="9.2"/>
                    <measurement group_id="O3" value="-0.3" spread="7.9"/>
                    <measurement group_id="O4" value="0.6" spread="7.3"/>
                    <measurement group_id="O5" value="0.0" spread="7.7"/>
                    <measurement group_id="O6" value="0.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="7.6"/>
                    <measurement group_id="O2" value="0.0" spread="9.7"/>
                    <measurement group_id="O3" value="-3.1" spread="7.9"/>
                    <measurement group_id="O4" value="1.3" spread="8.6"/>
                    <measurement group_id="O5" value="0.1" spread="7.3"/>
                    <measurement group_id="O6" value="-1.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="8.9"/>
                    <measurement group_id="O2" value="-0.3" spread="9.1"/>
                    <measurement group_id="O3" value="-1.2" spread="7.3"/>
                    <measurement group_id="O4" value="2.8" spread="8.7"/>
                    <measurement group_id="O5" value="-0.7" spread="7.7"/>
                    <measurement group_id="O6" value="-0.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="5.8"/>
                    <measurement group_id="O2" value="0.5" spread="6.3"/>
                    <measurement group_id="O3" value="-1.7" spread="6.4"/>
                    <measurement group_id="O4" value="3.1" spread="8.4"/>
                    <measurement group_id="O5" value="-1.1" spread="6.7"/>
                    <measurement group_id="O6" value="-1.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="8.5"/>
                    <measurement group_id="O2" value="-9.0" spread="9.1"/>
                    <measurement group_id="O3" value="0.8" spread="8.8"/>
                    <measurement group_id="O4" value="-4.5" spread="0.7"/>
                    <measurement group_id="O5" value="-9.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="-4.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)</title>
        <description>Pulse rate was measured in beats per minute (beats/min).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)</title>
          <description>Pulse rate was measured in beats per minute (beats/min).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="9.5"/>
                    <measurement group_id="O2" value="-1.6" spread="9.1"/>
                    <measurement group_id="O3" value="3.2" spread="8.0"/>
                    <measurement group_id="O4" value="-1.8" spread="8.1"/>
                    <measurement group_id="O5" value="0.1" spread="6.4"/>
                    <measurement group_id="O6" value="-0.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="8.4"/>
                    <measurement group_id="O2" value="-1.3" spread="9.9"/>
                    <measurement group_id="O3" value="1.1" spread="7.8"/>
                    <measurement group_id="O4" value="-1.0" spread="10.4"/>
                    <measurement group_id="O5" value="-2.2" spread="7.9"/>
                    <measurement group_id="O6" value="0.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="10.2"/>
                    <measurement group_id="O2" value="-3.1" spread="9.9"/>
                    <measurement group_id="O3" value="0.6" spread="7.8"/>
                    <measurement group_id="O4" value="-3.6" spread="9.0"/>
                    <measurement group_id="O5" value="-1.6" spread="6.5"/>
                    <measurement group_id="O6" value="1.6" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="9.8"/>
                    <measurement group_id="O2" value="1.2" spread="10.7"/>
                    <measurement group_id="O3" value="1.4" spread="8.3"/>
                    <measurement group_id="O4" value="-2.6" spread="9.7"/>
                    <measurement group_id="O5" value="-1.7" spread="9.3"/>
                    <measurement group_id="O6" value="2.6" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="8.9"/>
                    <measurement group_id="O2" value="-3.2" spread="9.3"/>
                    <measurement group_id="O3" value="0.4" spread="9.2"/>
                    <measurement group_id="O4" value="-1.8" spread="8.5"/>
                    <measurement group_id="O5" value="0.5" spread="8.2"/>
                    <measurement group_id="O6" value="0.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="8.4"/>
                    <measurement group_id="O2" value="-1.9" spread="6.8"/>
                    <measurement group_id="O3" value="1.8" spread="11.0"/>
                    <measurement group_id="O4" value="-3.1" spread="8.5"/>
                    <measurement group_id="O5" value="-1.7" spread="9.1"/>
                    <measurement group_id="O6" value="0.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.6"/>
                    <measurement group_id="O2" value="-2.5" spread="12.0"/>
                    <measurement group_id="O3" value="2.3" spread="6.0"/>
                    <measurement group_id="O4" value="1.5" spread="4.9"/>
                    <measurement group_id="O5" value="-7.0" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="7.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Temperature)</title>
        <description>Temperature was measured in degrees Celsius (°C).</description>
        <time_frame>Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Until Safety Follow-up Visit in Vital Signs (Temperature)</title>
          <description>Temperature was measured in degrees Celsius (°C).</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>°C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.23"/>
                    <measurement group_id="O2" value="-0.04" spread="0.22"/>
                    <measurement group_id="O3" value="0.02" spread="0.30"/>
                    <measurement group_id="O4" value="-0.11" spread="0.32"/>
                    <measurement group_id="O5" value="-0.07" spread="0.30"/>
                    <measurement group_id="O6" value="0.02" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.26"/>
                    <measurement group_id="O2" value="0.02" spread="0.26"/>
                    <measurement group_id="O3" value="0.01" spread="0.33"/>
                    <measurement group_id="O4" value="0.01" spread="0.35"/>
                    <measurement group_id="O5" value="-0.04" spread="0.36"/>
                    <measurement group_id="O6" value="-0.01" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.29"/>
                    <measurement group_id="O2" value="0.03" spread="0.24"/>
                    <measurement group_id="O3" value="0.00" spread="0.42"/>
                    <measurement group_id="O4" value="-0.04" spread="0.24"/>
                    <measurement group_id="O5" value="-0.03" spread="0.26"/>
                    <measurement group_id="O6" value="-0.01" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.29"/>
                    <measurement group_id="O2" value="-0.02" spread="0.25"/>
                    <measurement group_id="O3" value="-0.01" spread="0.22"/>
                    <measurement group_id="O4" value="-0.06" spread="0.43"/>
                    <measurement group_id="O5" value="-0.03" spread="0.38"/>
                    <measurement group_id="O6" value="0.07" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.24"/>
                    <measurement group_id="O2" value="-0.02" spread="0.28"/>
                    <measurement group_id="O3" value="0.00" spread="0.33"/>
                    <measurement group_id="O4" value="-0.03" spread="0.41"/>
                    <measurement group_id="O5" value="0.00" spread="0.35"/>
                    <measurement group_id="O6" value="0.02" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.27"/>
                    <measurement group_id="O2" value="0.00" spread="0.27"/>
                    <measurement group_id="O3" value="0.06" spread="0.36"/>
                    <measurement group_id="O4" value="-0.04" spread="0.28"/>
                    <measurement group_id="O5" value="0.00" spread="0.33"/>
                    <measurement group_id="O6" value="0.00" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.22"/>
                    <measurement group_id="O2" value="0.15" spread="0.33"/>
                    <measurement group_id="O3" value="-0.03" spread="0.05"/>
                    <measurement group_id="O4" value="0.10" spread="0.00"/>
                    <measurement group_id="O5" value="0.10" spread="NA">Value was not evaluable because only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="0.43" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Significant Physical Examination Abnormalities</title>
        <description>The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status.&#xD;
Any clinically significant abnormal findings during the study were captured as adverse events.</description>
        <time_frame>At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Physical Examination Abnormalities</title>
          <description>The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status.&#xD;
Any clinically significant abnormal findings during the study were captured as adverse events.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="9.3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings</title>
        <description>Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)</time_frame>
        <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Bimekizumab 64 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Bimekizumab 160 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Bimekizumab 160 mg w/ LD Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Bimekizumab 320 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Bimekizumab 480 mg Q4W (SS)</title>
            <description>Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings</title>
          <description>Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.</description>
          <population>The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SFU</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) were collected from Baseline (Week 0) to End of Safety Follow-up (up to Week 28)</time_frame>
      <desc>It was pre-specified to report adverse events (AE) that have a start date on or following the first administration of study treatment. TEAEs counts are for each study period: Treatment Period (Wk1-12) for all participants who received at least 1 study treatment and Post-Treatment Period for participants who either enrolled in an extension study (PS0011) or those who entered a 20-week Safety Follow-Up Period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (SS) Treatment Period</title>
          <description>During the Treatment Period participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E2">
          <title>Bimekizumab 64 mg Q4W (SS) Treatment Period</title>
          <description>During the Treatment Period participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.</description>
        </group>
        <group group_id="E3">
          <title>Bimekizumab 160 mg Q4W (SS) Treatment Period</title>
          <description>During the Treatment Period participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.</description>
        </group>
        <group group_id="E4">
          <title>Bimekizumab 160 mg w/ LD Q4W (SS) Treatment Period</title>
          <description>During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.</description>
        </group>
        <group group_id="E5">
          <title>Bimekizumab 320 mg Q4W (SS) Treatment Period</title>
          <description>During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.</description>
        </group>
        <group group_id="E6">
          <title>Bimekizumab 480 mg Q4W (SS) Treatment Period</title>
          <description>During the Treatment Period participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.</description>
        </group>
        <group group_id="E7">
          <title>Placebo (SS) Post-Treatment Period</title>
          <description>At Week 12, participants who were randomized to receive Placebo during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.&#xD;
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.</description>
        </group>
        <group group_id="E8">
          <title>Bimekizumab 64 mg Q4W (SS) Post-Treatment Period</title>
          <description>At Week 12, participants who were randomized to receive 64 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.&#xD;
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.</description>
        </group>
        <group group_id="E9">
          <title>Bimekizumab 160 mg Q4W (SS) Post-Treatment Period</title>
          <description>At Week 12, participants who were randomized to receive 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.&#xD;
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.</description>
        </group>
        <group group_id="E10">
          <title>Bimekizumab 160 mg w/ LD Q4W (SS) Post-Treatment Period</title>
          <description>At Week 12, participants who were randomized to receive 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.&#xD;
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.</description>
        </group>
        <group group_id="E11">
          <title>Bimekizumab 320 mg Q4W (SS) Post-Treatment Period</title>
          <description>At Week 12, participants who were randomized to receive 320 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.&#xD;
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.</description>
        </group>
        <group group_id="E12">
          <title>Bimekizumab 480 mg Q4W (SS) Post-Treatment Period</title>
          <description>At Week 12, participants who were randomized to receive 480 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.&#xD;
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1877 822 ext 9493</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

